They Use It Like Candy :  how the Prescription of Psychotropic Drugs to State-Involved Children Violates International Law by Burton, Angela Olivia
Brooklyn Journal of International Law
Volume 35 | Issue 2 Article 5
2010
"They Use It Like Candy": how the Prescription of
Psychotropic Drugs to State-Involved Children
Violates International Law
Angela Olivia Burton
Follow this and additional works at: https://brooklynworks.brooklaw.edu/bjil
This Article is brought to you for free and open access by the Law Journals at BrooklynWorks. It has been accepted for inclusion in Brooklyn Journal of
International Law by an authorized editor of BrooklynWorks.
Recommended Citation
Angela O. Burton, "They Use It Like Candy": how the Prescription of Psychotropic Drugs to State-Involved Children Violates International
Law, 35 Brook. J. Int'l L. (2010).
Available at: https://brooklynworks.brooklaw.edu/bjil/vol35/iss2/5
“THEY USE IT LIKE CANDY”: HOW THE 
PRESCRIPTION OF PSYCHOTROPIC DRUGS 
TO STATE-INVOLVED CHILDREN 
VIOLATES INTERNATIONAL LAW 
Angela Olivia Burton* 
 
INTRODUCTION ..................................................................................... 454 
I. SOME FACTS ABOUT PSYCHOTROPIC DRUGS .................................... 466 
II. INTERNATIONAL LAW GOVERNING PSYCHOTROPIC  
DRUGS: THE 1971 CONVENTION ........................................................... 468 
III. EPIDEMIC PSYCHOTROPIC DRUG PRESCRIBING  
TO UNITED STATES CHILDREN .............................................................. 471 
A. Psychotropic Drugs Are Prescribed to  
State-Involved Children at Alarming Rates ...................................... 472 
B. The 1990s: “Decade of the Brain” .............................................. 476 
IV. DIRECT-TO-CONSUMER ADVERTISING OF  
PSYCHOTROPIC DRUGS VIOLATES ARTICLE 10 OF  
THE 1971 CONVENTION ON PSYCHOTROPIC SUBSTANCES ................... 481 
V. THE PRESCRIPTION OF PSYCHOTROPIC DRUGS TO CHILDREN  
AS CURRENTLY PRACTICED IN THE UNITED STATES VIOLATES  
THE 1971 CONVENTION’S “MEDICAL PURPOSES” RESTRICTION .......... 490 
A. Chemical Restraint is Not a “Medical Purpose” ......................... 492 
B. Contesting the Characterization of Childhood  
Behavior as “Disease” ..................................................................... 496 
C. Treating Children with Psychotropic Drugs “Off-Label”: 
“Legitimate Medical Use”? .............................................................. 501 
D. Safer Alternatives to Psychotropic Drug Therapy  
Are Available .................................................................................... 505 
VI. PSYCHOTROPIC DRUGS ARE NOT PRESCRIBED TO  
CHILDREN IN STATE CUSTODY IN ACCORDANCE WITH  
SOUND MEDICAL PRACTICE ................................................................. 507 





 *  Associate Professor, City University of New York School of Law. I wish to thank 
my colleagues at City University of New York School of Law Rebecca Bratspies, Natalie 
Gomez-Velez, Jeff Kirchmeier and Ruthann Robson; Marty Guggenheim (New York 
University School of Law), and Jonathan Todres (Georgia State University College of 
Law) for their insightful suggestions, encouragement and support. 
454 BROOK. J. INT’L L. [Vol. 35:2 
 
“Psychotropic medications for young children should be used only 
when anticipated benefits outweigh risks. Parents should be fully in-
formed and decisions made only after carefully weighing these factors. 
Children and adolescents must be closely monitored and frequently 
evaluated as the side effects common to some medications can be par-
ticularly difficult for children. At the same time, psychotropic medica-
tions can be lifesaving.”1 
“They use it like candy,” said Elnorris Stone, a 25-year-old [Cali-
fornia Youth Authority] parolee from Oakland. “Anybody who’s con-
sidered hyper, who fights a lot, they prescribe it a lot. The medication 
fixes it.”2 
INTRODUCTION 
here is widespread concern that children in the United States are 
being severely overmedicated with psychotropic drugs. Psycho-
tropic drugs (also known as “psychoactive” or “psychiatric” drugs) act 
directly on the brain to affect behavior, emotion, or mood.3 Because they 
are toxic chemicals with great potential for addiction, abuse, and diver-
sion into the illegal drug trade, many are designated as controlled sub-
stances and their medicinal uses are stringently regulated by the interna-
tional community under the 1971 United Nations Convention on Psycho-
tropic Substances (“1971 Convention”).4 In 1995, the International Nar-
cotics Control Board (“INCB”), which monitors the implementation of 
the 1971 Convention,5 began to warn of an alarming increase in the pre-
scription of psychotropic drugs to children in the United States. The 
                                                                                                                                     
 1. DARCY E. GRUTTADARO & JOEL E. MILLER, NAMI POLICY RESEARCH INSTITUTE 
TASK FORCE REPORT: CHILDREN AND PSYCHOTROPIC MEDICATIONS 2 (2004), available at 
http://www.nami.org/Template.cfm?Section=press_room&Template=/ContentManageme
nt/ContentDisplay.cfm&ContentID=15721. 
 2. Nancy Price, They Use it Like Candy, STOCKTON REC., Jan. 16, 2000, available at 
http://www.sjcite.info/kidrights.html (reporting on the overuse of psychotropic medica-
tions among children in the custody of the California Youth Authority). 
 3. See RONALD T. BROWN & MICHAEL G. SAWYER, MEDICATIONS FOR SCHOOL-AGE 
CHILDREN: EFFECTS ON LEARNING AND BEHAVIOR 18 (1998); see also RITA WICKS-
NELSON & ALLEN C. ISRAEL, BEHAVIOR DISORDERS OF CHILDHOOD 67 (3d ed. 1997) 
(“Medications that affect mood, thought processes, or overt behavior are known as psy-
chotropic or psychoactive and thus the term psychopharmacological treatment is often 
employed.”). 
 4. See Convention on Psychotropic Substances, opened for signature Feb. 21, 1971, 
32 U.S.T. 543, 1019 U.N.T.S. 157 [hereinafter 1971 Convention]. 
 5. International Narcotics Control Board, Mandate of INCB, http://www.incb.org/ 
incb/en/mandate.html. 
T
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INCB was especially concerned about the astronomical rise in pediatric 
prescriptions of methylphenidate (i.e., Ritalin), an amphetamine-type 
stimulant drug most commonly prescribed to children diagnosed with 
Attention Deficit Hyperactivity Disorder (“ADHD”).6 Because of its high 
                                                                                                                                     
 6. In a press release issued in conjunction with the publication of its 1996 report, the 
INCB stressed that methylphenidate was one of the first substances placed under interna-
tional control in Schedule II of the 19712 Convention “due to its high abuse potential.” 
Press Release, United Nations Information Service, INCB Sees Continuing Risk in Sti-
mulant Prescribed for Children (Mar. 4, 1997), available at http://www.incb. 
org/pdf/e/press/1996/e_bn_04.pdf [hereinafter Continuing Stimulant Risk]. In its 1995 
Annual Report, the INCB pointed out that “3-5 per cent of all schoolchildren in the Unit-
ed States have reportedly been diagnosed as suffering from ADD [attention deficit dis-
order] and are treated with methylphenidate, frequently without the benefit of other forms 
of assistance recommended in treatment guidelines.” INT’L NARCOTICS CONTROL BD., 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD FOR 1995, para. 91 (1995), 
available at http://www.incb.org/incb/annual_report_1995.html. The Board noted an in-
crease in abuse of methylphenidate, mainly among “adolescents who illegally obtain the 
substance in tablet form from children undergoing treatment for ADD.” Id. The Board 
asked that U.S. authorities “carefully monitor future developments in the diagnosis of 
ADD in children and the extent to which methylphenidate and other stimulants (such as 
dexamfetamine and pemoline) are used in the treatment of ADD, in order to ensure that 
these substances are prescribed in accordance with sound medical practice as required 
under article 9, paragraph 2, of the 1971 Convention,” id. at para. 93, and urged all “Gov-
ernments to exercise the utmost vigilance in order to prevent ‘overdiagnosing’ of ADD in 
children and medically unjustified treatment with methylphenidate and other stimulants.” 
Id. at para. 94. 
  In virtually all of its annual reports since 1995, the INCB has pointed out to the 
United States its concerns about over-diagnosis of ADD/ADHD, the ever-increasing 
prescription rates, diversion, and abuse of methylphenidate and other internationally con-
trolled stimulants, and the persistence of direct-to-consumer advertising of psychotropic 
drugs. See INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL NARCOTICS 
CONTROL BOARD FOR 1996, para. 90–95 (1996), available at http://www.incb. 
org/incb/annual_report_1996.html; INT’L NARCOTICS CONTROL BD., REPORT OF THE 
INTERNATIONAL NARCOTICS CONTROL BOARD FOR 1997, para. 151–54 (1997), available 
at http://www.incb.org/incb/annual_report_1997.html; INT’L NARCOTICS CONTROL BD., 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD FOR 1998, para. 101, 121, 
134 (1998), available at http://www.incb.org/pdf/annual-report/1998/en/AR_08_English. 
pdf [hereinafter INCB 1998 REPORT]; INT’L NARCOTICS CONTROL BD., REPORT OF THE 
INTERNATIONAL NARCOTICS CONTROL BOARD FOR 1999, para. 159–65 (1999), available 
at http://www.incb.org/incb/annual_report_1999.html; INT’L NARCOTICS CONTROL BD., 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD FOR 2000, para. 1–49, 161–
65 (2000), available at http://www.incb.org/incb/annual_report_2000.html [hereinafter 
INCB 2000 REPORT] (extended discussion and analysis of “[o]verconsumption of interna-
tionally controlled drugs”); INT’L NARCOTICS CONTROL BD., REPORT OF THE 
INTERNATIONAL NARCOTICS CONTROL BOARD FOR 2001, para. 200–01, 341–43 (2001), 
available at http://www.incb.org/incb/annual_report_2001.html [hereinafter INCB 2001 
REPORT]; INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL NARCOTICS 
CONTROL BOARD FOR 2002, para. 173–76, available at http://www.incb.org/incb/annual 
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potential for abuse, methylphenidate was one of the first substances 
placed under international control in the 1971 Convention’s Schedule II,7 
which is reserved for drugs constituting a “substantial risk to public 
health,” while having only “little to moderate therapeutic usefulness.”8 
Although agreeing with the notion that “with proper diagnosis, stimu-
lants can be effective in treating [ADHD],”9 the INCB has consistently 
criticized the excessive pediatric prescription of internationally con-
trolled stimulant drugs in the United States, and has suggested that the 
high rates indicate an unjustified tendency to suppress and control nor-
mal childhood behaviors that adults (teachers and parents) find proble-
matic, rather than to treat legitimate medical conditions.10 
Concerns about overmedication are particularly pronounced with re-
spect to children in state custody. State-involved children11 are pre-
scribed psychotropic drugs at stunningly high rates, far higher than other 
                                                                                                                                     
_report_2002.html [hereinafter INCB 2002 REPORT]; INT’L NARCOTICS CONTROL BD., 
REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD FOR 2003, para. 181–88 
(2003), available at http://www.incb.org/incb/en/annual_report_2003.html [hereinafter 
INCB 2003 REPORT]; INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL 
NARCOTICS CONTROL BOARD FOR 2004, para. 145–49 (2004), available at 
http://www.incb.org/incb/annual_report_2004.html [hereinafter INCB 2004 REPORT]; 
INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL NARCOTICS CONTROL 
BOARD FOR 2005, para. 139, 374 (2005), available at http://www.incb.org/incb/annual_ 
report_2005.html; INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL 
NARCOTICS CONTROL BOARD FOR 2006, para. 87, 341 (2006), available at http://www. 
incb.org/incb/annual_report_2006.html [hereinafter INCB 2006 REPORT]; INT’L 
NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL NARCOTICS CONTROL BOARD 
FOR 2007, para. 128–29 (2005), available at http://www.incb.org/incb/annual_ 
report_2007.html; INT’L NARCOTICS CONTROL BD., REPORT OF THE INTERNATIONAL 
NARCOTICS CONTROL BOARD FOR 2008, para. 132–35, available at http://www.incb. 
org/incb/en/annual-report-2008.html [hereinafter INCB 2008 REPORT]. 
 7. See Continuing Stimulant Risk, supra note 6. 
 8. See infra Part II. 
 9. INCB 2000 REPORT, supra note 6, at para. 148. 
 10. See, for example, INCB 2000 REPORT, supra note 6, wherein the INCB expressed 
concern with “the frequent long-term use (beyond one year and sometimes indefinitely) 
of psychotropic substances for treating psychological reactions to social pressure without 
a diagnosis for a specific disorder.” Id. at para. 15. The Board further pointed out that 
“[c]orrecting mood and behavior through controlled drugs is becoming widespread,” id. 
at para. 16, and noted that “[t]he growing use of those substances for the treatment of 
school-age and also pre-school children, in the absence of universally accepted and vali-
dated definitions, diagnostic criteria and guidelines for such practice, has recently been 
the subject of concern.” Id. at para. 19. 
 11. As used in this Article, the term state-involved children refers generally to youths 
under the age of 18 who are in state foster care systems or incarcerated in juvenile prisons 
(“detention facilities”). 
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children in the general population.12 It has been estimated that about 8–
10% of children (six to eight million) under the age of 18 in the United 
States are prescribed medications for what are classified as mental health 
problems.13 In comparison, recent reports indicate that, on any given day, 
up to 50% or more of children in some state foster care systems and ju-
venile prisons receive psychotropic medications.14 
Given their often traumatic and unstable life experiences, it is unsur-
prising that many state-involved children exhibit emotional, cognitive, 
and behavioral symptoms associated with various psychiatric diagnos-
es.15 Where drug treatment predominates over psychosocial and beha-
                                                                                                                                     
 12. See, e.g., Utilization of Psychotropic Medication for Children in Foster Care: 
Hearing Before the Subcomm. on Income Security and Family Support of the H. Comm. 
On Ways & Means, 110th Cong., 2d sess. 6–14 (2008) (statement of Julie M. Zito, Pro-
fessor of Pharmacy and Psychiatry, Pharmaceutical Health Services Research, University 
of Maryland) [hereinafter Zito Testimony] (noting that youth in foster care and disabled 
youth “have the greatest likelihood of receiving complex, poorly evidenced, high cost 
medication regimens.”); Zima R. Raghavan et al., Psychotropic Medication Use in a 
National Probability Sample of Children in the Child Welfare System, 15 J. CHILD & 
ADOLESCENT PSYCHOPHARMACOLOGY 97, 97 (2005) (concluding that “children in child 
welfare settings are receiving psychotropic medications at a rate between 2 and 3 times 
that of children treated in the community”); Julie M. Zito et al., Psychotropic Medication 
Patterns Among Youth in Foster Care, 121 PEDIATRICS 157 (2008) (concluding that psy-
chotropic drug treatment is three to four times more common for youth in foster care who 
receive Medicaid as compared to other Medicaid-eligible youth) [hereinafter Psychotrop-
ic Medication Patterns]; Stacy Hagen & Laurie Orbeck, The Prescription of Psychotropic 
Medications in Foster Care Children: A Descriptive Study in St. Louis County—
Executive Summary, http://www.d.umn.edu/sw/executive/hstacy.html (summarizing a 
1998 study that concluded that 34.5% of children in foster care in St. Louis County, Min-
nesota were receiving psychotropic medication in comparison to 15% of children in the 
general population). 
 13. ST. LUKE’S HEALTH INITIATIVES, FLASHPOINT: CHILDREN, ADOLESCENTS AND 
PSYCHOTROPIC MEDICATIONS 10 (2006), available at http://www.slhi.org/publications/ 
issue_briefs/pdfs/ib-2006-August.pdf. 
 14. See infra Part II. 
 15. Michael W. Naylor et al., Psychotropic Medication Management for Youth in 
State Care: Consent, Oversight and Policy Considerations, CHILD WELFARE, Sept.–Oct. 
2007, at 175. “With few exceptions, youth in foster care have been physically or sexually 
abused, neglected or both,” id. at 176, and “children in foster care . . . have many unique 
risk factors, including emotional and physical sequelae of abuse and neglect, disrupted 
attachment relationships, and placement disruptions, which can all have an effect on clin-
ical presentation.” Id. at 178; see also AM. ACAD. OF CHILD AND ADOLESCENT 
PSYCHIATRY, AACAP POSITION STATEMENT ON OVERSIGHT OF PSYCHOTROPIC 
MEDICATION USE FOR CHILDREN IN STATE CUSTODY: A BEST PRINCIPLES GUIDELINE 
(2005), available at http://www.aacap.org/galleries/PracticeInformation/FosterCare_Best 
Principles_FINAL.pdf. 
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vioral interventions for children’s behavioral and mental health issues,16 
and where some doctors prescribe multiple psychotropic drugs even to 
very young children without any evidence of their pediatric safety or ef-
fectiveness,17 these already vulnerable state-involved children are at par-
ticular risk for overmedication with psychotropic drugs.18 
Speaking precisely to this issue, the 1971 Convention establishes an in-
ternational monitoring and control system to protect the public from dan-
gers associated with psychotropic drugs. By signing that treaty, the Unit-
ed States and other signatory countries agreed to abide by provisions de-
signed to protect the public—including children—from unwarranted ex-
posure to these highly toxic and addictive drugs. Yet, as will be further 
illustrated, conditions and policies persist in the United States that violate 
the 1971 Convention and threaten the health, well-being, and, indeed, the 
very lives, of thousands of state-involved children.19 
While a primary emphasis of the 1971 Convention was the minimiza-
tion of the substantial risks to the public health posed by unregulated and 
excessive availability of psychotropic drugs, the Convention recognizes 
that, when administered under strictly controlled conditions, the drugs 
may provide limited medical benefit.20 To ensure that they are used as 
                                                                                                                                     
 16. See, e.g., Encarnacion Pyle, Even Babies Getting Treated as Mentally Ill: Pre-
scriptions on the Rise Even Though They Haven’t Been Tested on Children, COLUMBUS 
DISPATCH, Apr. 25, 2005, at A1, available at http://www.dispatch.com/live/contentbe/ 
dispatch/2005/04/25/20050425-A1-00.html. The biggest public-health crisis facing the 
state and nation is the number of children with mental illness who fail to receive any care 
or treatment,” said Michael Hogan, director of the Ohio Department of Mental Health. Id. 
“It’s true children are more likely to get medication than counseling or other behavioral 
therapy if they go to their pediatrician or family doctor. But at the end of the day, meds 
are quite safe and effective.” Id. 
 17. Psychotropic Medication Patterns, supra note 12, at 162 (pointing out that al-
though children in foster care, as a group, experience substantially more psychiatric dis-
orders than non-foster care children, there is no basis for concluding that dispensing 3 or 
more “different psychotropic medication classes concomitantly to children in foster care 
represents a treatment advantage.”). 
 18. See Susan dosReis et al., Mental Health Services for Youths in Foster Care and 
Disabled Youths, 91 AM. J. PUB. HEALTH 1094 (2001). 
 19. See, e.g., GABRIEL MYERS WORK GROUP, FLA. DEP’T OF CHILDREN & FAMILY 
SERV., REPORT OF GABRIEL MYERS WORK GROUP (2009), available at http://www.dcf. 
state.fl.us/initiatives/GMWorkgroup/docs/GabrielMyersWorkGroupReport082009Final.p
df (detailing the panel’s findings regarding the apparent suicide of Gabriel Myers, a 7-
year old foster child, and the extent that the use of multiple psychotropic drugs was a 
contributing factor to his death); see also Carol Marbin Miller, Child-Welfare Panel: 
Drugs Misused on Foster Kids, MIAMI HERALD, Aug. 13, 2009, http://www.miamiherald. 
com/2009/08/12/v-print/1183698/child-welfare-panel-drugs-misused.html (reporting on 
Gabriel Myers Work Group report). 
 20. 1971 Convention, supra note 4, preamble. 
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medicines only where the potential benefits clearly outweigh the poten-
tial public health risks, the 1971 Convention imposed a number of specif-
ic restrictions on the use of psychotropic drugs. First and foremost, their 
use is strictly limited to legitimate “medical and scientific purposes.”21 
And, to prevent undue influence by commercial interests on the public’s 
perception and understanding of their risks and benefits, the Convention 
requires the United States government to prohibit advertising of psycho-
tropic drugs to the general public “with due regard to its constitutional 
provisions.”22 To minimize improper use, psychotropic drug labels must 
indicate such “cautions and warnings . . . as in [the government’s] opi-
nion are necessary for the safety of the user.”23 Further, the federal gov-
ernment must ensure that prescriptions for psychotropic drugs are issued 
“in accordance with sound medical practice and subject to such regula-
tion . . . as will protect the public health and welfare.”24 In addition, the 
Convention provides that a government may adopt “more strict or severe 
measures of control” than those provided for in the 1971 Convention, “if 
in its opinion, such measures are desirable or necessary for the protection 
of the public health and welfare.”25 Despite these internationally agreed-
upon safeguards, the United States government persists in its failure to 
comply with these important mandates, putting the health and safety of 
hundreds of thousands of children at risk from illegitimate exposure to 
psychotropic drugs. 
The vast majority of psychotropic drugs are prescribed to children 
“off-label”—that is, without the benefit of the same rigorous, scientific, 
clinically-derived safety and efficacy data required by the Food and Drug 
Administration (“FDA”) in the United States for approval of drugs pre-
scribed to adults.26 The resulting absence of child-specific warnings or 
cautions as required by the 1971 Convention leaves to physicians the 
risky business of dispensing highly toxic, brain-targeting chemicals to 
still-developing children, with little more than small scale, anecdotal evi-
dence from short-term experiments for the safety and efficacy of such 
chemicals.27 The importance of regulatory approval and proper labeling 
                                                                                                                                     
 21. Id. at art. 5. 
 22. Id. at art. 10(2). 
 23. Id. at art. 10(1). 
 24. Id. at art. 9. 
 25. Id. at art. 23. 
 26. See GLENN R. ELLIOTT & KATE KELLY, MEDICATING YOUNG MINDS: HOW TO 
KNOW IF PSYCHIATRIC DRUGS WILL HELP OR HURT YOUR CHILD 22 (2006). 
 27. Id. Elliott and Kelly noted that doctors prescribe medication off-label because: 
small experiments and anecdotal evidence says it works . . . if the medication 
seems to help, the clinician may publish what is called a case report, or simply 
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is underscored by the fact that even drugs that have been approved by the 
FDA can cause serious risks to children’s health and safety. For example, 
in 2005, the FDA withdrew approval for pemoline (marketed as Cylert), 
a stimulant drug listed in Schedule II of the 1971 Convention.28 Pemo-
line, which was commonly used to treat children diagnosed with atten-
tion deficit hyperactivity disorder (ADHD), was ordered off the markets 
after the FDA found evidence that “the overall risk of liver toxicity from 
Cylert and generic pemoline products outweighs the benefits of this 
drug.”29 
Another recent incident involved concerns about the safety of Adderall 
XR, another drug widely used for the treatment of ADHD in children. 
The main ingredient in Adderall XR is amphetamine, a Schedule II sub-
stance under the 1971 Convention.30 Approved by the FDA for use by 
children age six and older in 2001,31 it was removed from the market in 
2005 by the Canadian government in the wake of 20 reports of sudden 
unexplained death (“SUD”) amongst children who had taken the drug.32 
The Canadian government returned Adderall XR to the shelves a few 
                                                                                                                                     
tell colleagues, who pass it on to other colleagues . . . . This type of work, often 
just clinical reports based on a few patients, is much simpler, faster and far 
cheaper than what the FDA requires. However, it is plagued with uncertainties 
about genuine efficacy and safety. 
Id. at 23. To fill the gap left by the federal drug regulatory agency, the American Acade-
my of Child and Adolescent Psychiatry advises physicians to “consider data from studies 
in adults in treating the target disorder and/or symptomatology, any clinical or anecdotal 
reports of use in child and adolescent patients, studies conducted outside the United 
States and the experience of colleagues.” American Academy of Child and Adolescent 
Psychiatry, Prescribing Psychoactive Medication for Children and Adolescents (2001), 
available at http://www.aacap.org/cs/root/policy_statements/prescribing_psychoactive_ 
medication_for_children_and_adolescents. 
 28. For a description of scheduling of psychotropic substances under the 1971 Con-
vention, see infra Part II. 
 29. U.S. Food & Drug Admin., Alert for Healthcare Professionals: Pemoline Tablets 
and Chewable Tablets (marketed as Cylert) (Oct. 2005), http://www.fda.gov/downloads/ 
Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm12646
2.pdf. 
 30. INT. NARCOTICS REVIEW BD., LIST OF PSYCHOTROPIC SUBSTANCES UNDER 
INTERNATIONAL CONTROL 5 (2003), available at http://www.incb.org/pdf/e/list/green.pdf 
[hereinafter GREEN LIST]. 
 31. Centerwatch, Newly Approved Drug Therapies, Adderall XR, http://www.center 
watch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=725. 
 32. U.S. Food & Drug Admin., Public Health Advisory for Adderall and Adderall XR 
(Feb. 9, 2005), available at http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ 
ucm051672.htm. 
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months later with additional safety warnings.33 However, while it ac-
knowledged the evidence of the sudden deaths, the FDA declined at that 
time to take any action, stating that it could not “conclude that recom-
mended doses of Adderall can cause SUD,” but that it was “continuing to 
carefully evaluate these data.34 Two years later, in 2007, the FDA di-
rected manufacturers of all drugs approved for the treatment of ADHD to 
develop “Patient Medication Guides” as part of their product labeling to 
highlight for patients the potential for increased risk of heart-related 
problems such as sudden death, stroke, and heart attacks, as well as in-
creased risk of adverse psychiatric symptoms such as “hearing voices, 
becoming suspicious for no reason, or becoming manic, even in patients 
who did not have previous psychiatric problems.”35 
Serious concerns have also arisen in recent years about the safety of 
psychotropic drugs that are not controlled under the 1971 Convention, 
but for which many of the same safety, efficacy, and effectiveness con-
cerns exist. A recent example is the case of selective serotonin reuptake 
inhibitors (“SSRIs”), a class of antidepressants often prescribed to child-
ren for symptoms associated with depression and anxiety disorders, in-
cluding drugs such as setraline hydrochloride (marketed as Zoloft), pa-
roxetine (marketed as Paxil), and fluoxetine (marketed as Prozac, which 
currently is the only medication approved by the FDA for use in treating 
depression in children age eight and older).36 In 2003, amidst evidence of 
increased risk of suicidal thoughts and actions among children and ado-
lescents treated with SSRIs, Britain’s FDA equivalent, the British Medi-
cines and Healthcare Products Regulatory Agency, strongly recommend-
ed that physicians stop prescribing SSRIs (excluding Prozac) to child-
ren,37 citing evidence that that the drugs “may do more harm than good 
in the treatment of depression in under-18s.”38 Although declining to 
                                                                                                                                     
 33. U.S. Food & Drug Admin., Adderall and Aderall XR (amphetamines) Informa-
tion (Aug. 2005), available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug 
SafetyInformationforPatientsandProviders/ucm111441.htm. 
 34. Id. 
 35. Press Release, U.S. Food & Drug Admin., FDA Directs ADHD Drug Manufac-
turers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse 
Events (Feb. 21, 2007), available at http://www.fda.gov/NewsEvents/Newsroom/Press 
Announcements/2007/ucm108849.htm. 
 36. See Nat’l Inst. of Mental Health, Treatment of Anxiety Disorders, http://www. 
nimh.nih.gov/health/publications/anxiety-disorders/treatment-of-anxiety-disorders.shtml. 
 37. Erica Goode, British Warning on Antidepressant Use for Youth, N.Y. TIMES, Dec. 
11, 2003, at A1; see also Shankar Vedantam, Britain Warns Against Giving Newer Anti-
depressants to Kids: Only Prozac’s Benefits Outweigh Risks, Health Officials Say, WASH. 
POST, Dec. 11, 2003, at A2. 
 38. Vendatam, supra note 37; see also Goode, supra note 37. 
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recommend against pediatric use of SSRIs at that time, two years later 
the FDA required that the labeling for all antidepressants include a 
“black box” warning—the most serious warning placed on the labeling 
of a prescription medication—about the increased risk of suicide to 
children.39 More recently, a 2008 study that analyzed data from clinical 
trials found little evidence that the antidepressants studied were any more 
effective than a placebo in alleviating depression.40 
In addition to their numerous safety risks, many of the touted benefits 
of psychotropic drugs to children are often highly overstated.41 Despite 
the fact that stimulant drugs such as Ritalin (containing methylphenidate, 
a 1971 Convention Schedule II drug) are among the most studied with 
respect to their effects on children, “essentially nothing” was known until 
recently “about the long-term benefits and problems of stimulant treat-
                                                                                                                                     
 39. Press Release, U.S. Food & Drug Admin., FDA Launches a Multi-Pronged Strat-
egy to Strengthen Safeguards for Children Treated with Antidepressant Medications (Oct. 
15, 2004), available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 
2004/ucm108363.htm. An FDA report published in August 2009 and co-authored by Dr. 
Marc Stone, a senior medical reviewer in the FDA’s Center for Drug Evaluation and 
Research, confirmed that SSRIs increase the risk of suicidal thoughts or behavior in 
children and adolescents, and extended the warnings to young adults aged 18–25. MARC 
STONE ET AL., RISK OF SUICIDALITY IN CLINICAL TRIALS OF ANTIDEPRESSANTS IN ADULTS: 
ANALYSIS OF PROPRIETARY DATA SUBMITTED TO US FOOD AND DRUG ADMINISTRATION 5 
(2009), available at http://www.bmj.com/cgi/content/abstract/339/aug11_2/b2880. 
 40. Irving Kirsch et al., Initial Severity and Antidepressant Benefits: A Meta-Analysis 
of Data Submitted to the Food and Drug Administration, 5 PLOS MEDICINE 260, 256–66 
(2008), available at http://medicine.plosjournals.org/archive/1549-1676/5/2/pdf/10.1371_ 
journal.pmed.0050045-L.pdf. But see Jeffrey A. Bridge et al., Clinical Response and Risk 
for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treat-
ment: A Meta-analysis of Randomized Controlled Trials, 297 J. AM. MED. ASS’N 1683, 
1683 (2007) (suggesting that the benefits of antidepressant medications likely outweigh 
their risks to children and adolescents diagnosed with major depression and anxiety dis-
orders). 
 41. See Zito Testimony, supra note 12, at 9 (“Post-marketing studies are particularly 
important to identify and describe patient outcomes in terms of academic performance, 
social development and avoidance of negative outcomes, e.g. crime, substance abuse and 
school failure—in other words, beyond symptom control. In the current U.S. research 
environment, most medication research focuses on symptom improvement in short-term 
clinical trials which is necessary but not sufficient information to establish the role of 
medication in community-based pediatric populations.”); see also WORKING GROUP ON 
PSYCHOACTIVE MEDICATIONS FOR CHILDREN AND ADOLESCENTS, AM. PSYCHOLOGICAL 
ASS’N, REPORT OF THE WORKING GROUP ON PSYCHOACTIVE MEDICATIONS FOR CHILDREN 
AND ADOLESCENTS PSYCHOPHARMACOLOGICAL, PSYCHOSOCIAL, AND COMBINED INTER-
VENTIONS FOR CHILDHOOD DISORDERS: EVIDENCE BASE, CONTEXTUAL FACTORS, AND 
FUTURE DIRECTION 25 (2006) (noting that “[u]nfortunately, growing evidence suggests 
that outcomes achieved in real-world community settings pale in comparison to those 
obtained in evidence-based clinical trials for both psychotherapy and medication.”). 
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ment for ADHD and how early treatment may affect adolescence and 
adulthood.”42 This situation changed dramatically in February 2010 when 
the Government of Western Australia released the Raine ADHD Study, 
which analyzes longitudinal data collected on 2,868 children from birth 
through age 14 as part of the Western Australian Pregnancy Birth Co-
hort.43 Described as the first study to provide “a unique long-term view 
of a wide range of outcomes and their associations with the use of stimu-
lant medication in the treatment of ADHD,” the project examines “the 
long-term social, emotional, school-based, growth, and cardiovascular 
outcomes associated with the use of stimulant medication in the treat-
ment of ADHD.”44 Notably, children diagnosed with ADHD who had 
been treated with stimulants were found to be 10.5 times more likely to 
have been identified by a classroom teacher as performing below age-
level, and had “significantly greater diastolic blood pressure than child-
ren who had never received medication.”45 While noting that limitations 
of the study “prevent any strong causal relationships from being identi-
fied, the authors suggested that the “lack of significant improvements in 
long-term social, emotional, and academic functioning associated with 
the use of stimulant medication” in the subject children indicates that 
further research is warranted “to better understand the suspected long-
term social, emotional and educational benefits of stimulant medication 
in the treatment of ADHD.” 46 
The safety risks and overstatement problems described above are com-
pounded by the fact that, in direct contravention of explicit provisions of 
the 1971 Convention, advertisements not only extoll the claimed virtues 
of various psychotropic drugs ubiquitous in the United States, they also 
frequently make false and/or misleading claims about the drugs47 while 
simultaneously downplaying significant and serious risks.48 
                                                                                                                                     
 42. ELLIOTT & KELLY, supra note 26, at 202–03. 
 43. See GRANT SMITH ET AL., RAINE ADHD STUDY: LONG-TERM OUTCOMES 
ASSOCIATED WITH STIMULANT MEDICATION IN THE TREATMENT OF ADHD IN CHILDREN 
(2010), available at http://www.health.wa.gov.au/publications/documents/MICADHD_Raine 
_ADHD_Study_report_022010.pdf. 
 44. Id. at 5. 
 45. Id. at 6. 
 46. Id. at 8 (emphasis added). 
 47. See CTR. FOR DRUG EVALUATION AND RESEARCH, U.S. FOOD & DRUG ADMIN., 
2005 REPORT TO THE NATION: IMPROVING PUBLIC HEALTH THROUGH HUMAN DRUGS 45 
(2005), available at http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ 
WhatWeDo/UCM078935.pdf. In 2005, the Center for Drug Evaluation and Research 
(CDER) (a division of the Food and Drug Administration which monitors advertising of 
prescription drugs and issues regulatory action letters to companies), issued 60 letters to 
drug companies for “prescription drug promotions deemed to be false, misleading, lack-
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Although others have addressed some of the vexing problems related 
to the use of psychotropic drugs in children,49 none has examined the 
obligations of the United States government under international law. This 
Article argues that the United States government has violated interna-
tional law by failing to implement important mandates of the 1971 Con-
vention, and this has significantly contributed to the unconscionable rise 
in unwarranted prescription and inappropriate administration of psycho-
tropic drugs to children in state foster care systems and juvenile prisons 
in the U.S. 
In Part I of this Article, I present a brief and grossly oversimplified ex-
planation of the essential nature of psychotropic medications and how 
they interact with the human body. In Part II, I delineate the provisions 
                                                                                                                                     
ing in fair balance of risks and benefits or that promoted a product or indication before 
approval.” Id. 
  For an example of such a warning letter, see Letter from Robert Dean, Group 
Leader, Food & Drug Admin., to Kathryn Roberts, Director, Johnson and Johnson (Sept. 
25, 2008), available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceReg 
ulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLet 
terstoPharmaceuticalCompanies/ucm053998.pdf [hereinafter Johnson and Johnson Warn-
ing Letter]. This letter cites Johnson & Johnson for their advertisements of Concerta, 
whose active ingredient is methylphenidate, an internationally controlled drug under the 
1971 Convention. The letter asserts that the subject ad was misleading because it over-
stated Concerta’s efficacy by implying “that use of Concerta will lead to an improvement 
in academic performance throughout the day when this has not been shown by substantial 
evidence or clinical experience.” Id. at 2. The letter also deemed a webpage entitled “Af-
ter School,” to be misleading because it asserted “improvement with Concerta in a broad 
array of adolescent after school activities, such as athletics, clubs, and performance in 
part-time jobs, when this has not been demonstrated by substantial evidence.” Id. at 3. 
The letter observes that, “[w]hile Concerta has been shown to improve total scores on the 
Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS), which measures 
ADHD symptoms such as fidgeting, not listening, and talking excessively, what has not 
been shown is that this improvement in ADHD-RS total scores is correlated with a posi-
tive effect on adolescents’ ability to pursue interests and hobbies outside of school and to 
do “well in all areas of [their] daily life.” Id. Other Concerta promotional material was 
found to be misleading because they omitted “material facts regarding the risk of long-
term growth suppression” from treatment with the drug. Id. 
 48. Johnson and Johnson Warning Letter, supra note 47, at 3. 
 49. See, e.g., Connie Lenz, Prescribing a Legislative Response: Educators, Physi-
cians, and Psychotropic Medication for Children, 22 J. CONTEMP. HEALTH L. & POL’Y 72 
(2005); Stephen A. Talmadge, Who Should Determine What is Best for Children in State 
Custody Who Object to Psychotropic Medication?, 15 ANNALS HEALTH L. 183 (2006); 
Jennifer Albright, Comment, Free Your Mind: The Right of Minors in New York to 
Choose Whether or Not to be Treated with Psychotropic Drugs, 16 ALB. L. J. SCI. & 
TECH. 169 (2006); Maggie Brandow, Note, A Spoonful of Sugar Won’t Help This Medi-
cine Go Down: Psychotropic Drugs for Abused and Neglected Children, 72 S. CAL. L. 
REV. 1151, 1152 (1999). 
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and terms of the 1971 Convention that serve as the primary international 
legal authority governing the manufacture, distribution, and use of psy-
chotropic drugs.50 These provisions, which will be analyzed individually 
in subsequent sections of this Article, include: a prohibition of direct-to-
consumer advertising of psychotropic drugs, a limitation on use (for 
“medical purposes” only), and a mandate that prescriptions be issued in 
accordance with sound medical practice. Also, though it has not yet been 
ratified in the U.S., I will briefly outline in this part some of the impor-
tant human rights principles embodied in the United Nations Convention 
on the Rights of the Child to further illuminate the United States gov-
ernment’s positive law obligations to state-involved children under the 
1971 Convention. 
With that grounding, I will detail in Part III the shockingly high rates 
of psychotropic drug prescription to state-involved children. Throughout 
the country, on any given day, thousands of children in state custody are 
administered a variety of psychotropic drugs despite the known toxicities 
and addictive properties of these drugs. Ultimately, I will argue that the 
rise of this problematic trend is at least partially attributable to govern-
mental policies instituted during the “Decade of the Brain,” a period in 
the 1990s when the National Institute of Mental Health shifted its re-
search focus from psychosocial and behavioral interventions to an em-
phasis on drug treatment as the first-line response to children’s mental 
health problems. 
In Part IV, I link the overmedication phenomenon to the United States’ 
failure to prohibit direct-to-consumer advertising of psychotropic drugs 
despite the 1971 Convention’s mandate and the nation’s failure to regu-
late the off-label prescription of these drugs to children in violation of the 
Convention’s “medical purposes” requirement. I argue that these  
governmental omissions are in direct violation of the 1971 Convention 
and are major contributors to the excessive and inappropriate medication 
of state-involved children. 
In Part V, I address the argument that current practices in the United 
States run afoul of the 1971 Convention’s requirement that governments 
allow the use of psychotropic medications only for legitimate medical 
purposes. I argue that the United States government is in violation of the 
1971 Convention for failing to prevent the use of psychotropic drugs as 
chemical restraints against state-involved children and for failing to en-
sure that state-involved children are not inappropriately prescribed psy-
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Finally, in Part VI, I draw on investigative research and government 
reports detailing substantial departures from generally accepted profes-
sional standards of diagnosis, monitoring, and follow-up in the adminis-
tration of psychotropic drugs to children in state foster care systems and 
juvenile prisons, all to analyze how these egregious practices violate the 
1971 Convention’s mandate that psychotropic drugs be administered in 
accordance with sound medical practice. Then, in conclusion, I call on 
the United States government to implement regulations and other appro-
priate measures to ensure compliance with its international legal obliga-
tion to protect state-involved children from non-medically-justified ad-
ministration of psychotropic drugs. 
I. SOME FACTS ABOUT PSYCHOTROPIC DRUGS 
As a class, psychotropic drugs are toxic substances that act directly on 
the brain to “chemically alter mood, cognition, or behavior, their effect 
typically being achieved by altering the process of brain neurotransmis-
sion.”51 There are generally six classes of psychotropic medications: sti-
mulants,52 antipsychotics,53 depressants, antidepressants,54 anxyiolitics (an-
ti-anxiety),55 and mood stabilizers.56 These drugs are prescribed to child-
                                                                                                                                     
 51. THOMAS GRISSO, DOUBLE JEOPARDY: ADOLESCENT OFFENDERS WITH MENTAL 
DISORDERS 84 (2004); see also RITA WICKS-NELSON & ALLEN C. ISRAEL, supra note 3, at 
67 (“Medications that affect mood, thought processes, or overt behavior are known as 
psychotropic or psychoactive and thus the term psychopharmacological treatment is often 
employed.”). 
 52. Stimulants such as dextroamphetamine (Adderall, Dexedrine) and methylpheni-
date (Ritalin, Concerta) are used primarily to treat Attention Deficit Hyperactivity Dis-
order (“ADHD”). BROWN & SAWYER, supra note 3, at 91; see also NAT’L INST. OF 
MENTAL HEALTH, TREATMENT OF CHILDREN WITH MENTAL DISORDERS (2009), available 
at http://www.nimh.nih.gov/publicat/childqa.cfm. 
 53. Antipsychotic medications such as chlorpromazine (Thorazine), haloperidol (Hal-
dol), clozapine (Clozaril), quetiapine (Seroquel), and rispiridone (Risperdal) are used for 
psychosis (e.g., schizophrenia, mania, psychotic depression), severe ADHD unresponsive 
to other treatments, conduct disorder, and problematic behaviors such as uncontrollable 
agitation, aggression, or rage, self-injurious behaviors, and extreme impulsivity. ELLIOTT 
& KELLY, supra note 26, at 185; see also BROWN & SAWYER, supra note 3, at 33–34, 99–
106. 
 54. Physicians prescribe antidepressants to children for such diverse conditions as 
depression, anxiety disorders, ADHD, bulimia, bedwetting, obsessive-compulsive disord-
er, and post-traumatic stress disorder, as well as uncontrollable agitation, aggression, 
obsessive behaviors, and self-injurious behaviors. ELLIOTT & KELLY, supra note 26, at 
174. 
 55. Antianxiety or anxiolytic medications are typically used for anxiety disorders, 
behavior disorders, seizures, and panic attacks. See generally BROWN & SAWYER, supra 
note 3, at 32–33; ELLIOTT & KELLY, supra note 26, at 214–24. 
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ren for conditions such as ADHD, obsessive-compulsive disorder 
(“OCD”), depression, and bipolar (manic-depressive) disorder, as well as 
for non-disorder-specific behaviors such as severe aggression, sleep 
problems, and bedwetting.57 
Best practices dictate that psychotropic drugs should be used only as a 
last resort, and never as the sole approach to addressing children’s mental 
health needs.58 The National Institute of Mental Health identifies a range 
of psychotherapies available to address mental health needs, including: 
cognitive behavioral therapy, dialectical behavior therapy, interpersonal 
therapy, and family-focused therapy, as well as other nonpharmaceutical 
approaches, such as light therapy, expressive or creative arts therapy, 
animal-assisted therapy, and play therapy.59 Advocates of drug therapy 
claim that psychotropic drugs help stabilize behaviors and emotions that 
impair the abilities of some children to function at home, in school, and 
in interactions with their peers.60 However, proponents recognize that 
these drugs can also worsen existing problems or create entirely new 
ones.61 The risks posed by psychotropic drugs to the health and safety of 
children range from the fairly innocuous—e.g., dry mouth and head-
ache—to more serious side effects, such as thyroid dysfunction, growth 
retardation, increased risk for polycystic ovary syndrome, abnormal 
weight gain, liver damage, heart failure, and death.62 
                                                                                                                                     
 56. Doctors prescribe mood stabilizers, including drugs such as lithium and the anti-
convulsants (Depakote) and carbamazepine (Tegretol), for bipolar disorder, conduct dis-
order, aggressive behaviors, and labile mood with tantrums or rages. ELLIOTT & KELLY, 
supra note 23, at 115–17. See generally, BARBARA A. LEADHOLM, PSYCHOACTIVE 
MEDICATIONS FOR CHILDREN AND ADOLESCENTS: ORIENTATION FOR PARENTS, 
GUARDIANS, AND OTHERS 7–12 (rev. 2007), available at http://www.mass.gov/Eeohhs2/ 
docs/dmh/publications/psychoactive_booklet.pdf. 
 57. See Psychiatric Medication for Children and Adolescents Part I—How Medica-
tions are Used, FACTS FOR FAMILIES, (Am. Acad. of Child & Adolescent Psychiatry, 
Washington, D.C.), July 2004, available at http://www.aacap.org/galleries/FactsFor 
Families/21_psychiatric_medication_for_children_and_adolescents_part_one.pdf. 
 58. See, e.g., CHILD WELFARE LEAGUE OF AM., STANDARDS OF EXCELLENCE FOR 
HEALTH CARE SERVICES FOR CHILDREN IN OUT-OF-HOME CARE 18 (Julie Gwin ed., rev. 
ed. 2007) (“Psychiatrists specializing in the treatment of children advise that psychotropic 
medication should not be used as the sole treatment for children with mental health dis-
orders.”). 
 59. National Institute of Mental Health, Psychotherapies, http://www.nimh.nih.gov/ 
health/topics/psychotherapies/index.shtml. 
 60. See GRUTTADARO & MILLER, supra note 1, at 6. 
 61. ELLIOTT & KELLY, supra note 26, at 9. 
 62. See, e.g., Christoph U. Correll & Harold E. Carlson, Endocrine and Metabolic 
Adverse Effects of Psychotropic Medications in Children and Adolescents, 45 J. AM. 
ACAD. CHILD & ADOLESCENT PSYCHIATRY 771 (2006); see also FLA. STATEWIDE 
ADVOCACY COUNCIL, RED ITEM REPORT: PSYCHOTROPIC DRUG USE IN FOSTER CARE 4 
468 BROOK. J. INT’L L. [Vol. 35:2 
Although many of the psychotropic drugs that are prescribed to child-
ren are not subject to international control, they nevertheless can raise the 
same significant safety and health concerns sought to be addressed by 
provisions of the 1971 Convention examined in this Article. These in-
clude: antidepressants (e.g., tricyclics such as clomipramine (Anafranil) 
and imipramine (Tofranil); SSRIs (e.g., escitalopram (Lexapro), fluoxe-
tine (Prozac), paroxetine (Paxil), and sertraline (Zoloft)); typical and 
atypical antipsychotics (e.g., chlorpromazine (Thorazine), haloperidol 
(Haldol), aripiprazole (Abilify), quetiapine (Seroquel), risperidone (Ris-
perdal), and ziprasidone (Geodon)); and mood stabilizers (e.g., Lithium, 
carbamazepine (Tegretol), and valproic acid (Depakote)).63 The medica-
tions commonly prescribed to children that are deemed to be “controlled 
substances” are listed on the 1971 Convention’s “Green List,” and in-
clude: Schedule II methylphenidates and amphetamines primarily used to 
treat ADD/ADHD (e.g., methylphenidates marketed as Concerta, Foca-
lin, Metadata, Methylin, and Ritalin, and amphetamines marketed as Ad-
derall, Dextrostate, and Dexedrine); Schedule IV benzodiazapines, pri-
marily used as anti-anxiety agents (e.g., alprazolam (Xanax), clonazapam 
(Klonopin), diazepam (Valium), and lorazepam (Ativan)); and the non-
benzoadiazapine sleep agent zolpidem (Ambien).64 As described in the 
next section, the 1971 Convention mandates that governments implement 
and enforce strict controls over the prescription and use of Green List 
drugs. 
II. INTERNATIONAL LAW GOVERNING PSYCHOTROPIC DRUGS: THE 1971 
CONVENTION 
Due to the limited therapeutic value, highly addictive properties, and 
susceptibility to illegal trafficking of psychotropic drugs, the 1971 Con-
vention65 establishes strict guidelines for governmental control over the 
use of such drugs. Thus, while it recognizes that “the use of psychotropic 
substances for medical and scientific purposes is indispensable and that 
their availability for such purposes should not be unduly restricted,”66 the 
Convention emphasizes that “rigorous measures are necessary to restrict 
the use of such substances to legitimate purposes.”67 
                                                                                                                                     
(2003), available at http://psychrights.org/States/Florida/030701FloridaStatewideAdvocacy 
CouncilReport.pdf; GRISSO, supra note 51, at 90. 
 63. See generally ELLIOTT & KELLY, supra note 26, at 151–224. 
 64. See GREEN LIST, supra note 30, at 5. 
 65. See 1971 Convention, supra note 4, preamble. 
 66. Id. 
 67. Id. 
2010] "THEY USE IT LIKE CANDY" 469 
The World Health Organization (“WHO”) has sole responsibility for 
evaluating and making recommendations to the Commission on Narcotic 
Drugs about the level of international control to be applied to a particular 
drug.68 Placement of a drug in a particular “Schedule” indicates the 
WHO’s determination as to the balance between a drug’s potential for 
abuse and its medical usefulness. Accordingly, more restrictive controls 
are imposed as the potential for abuse increases and the medical useful-
ness of a particular psychotropic drug decreases. For example, sub-
stances such as lysergide (“LSD”) are placed in Schedule 1, indicating 
that its “liability to abuse constitutes an especially serious risk to public 
health” and that it has “very limited, if any, therapeutic usefulness.”69 
Amphetamines (e.g., Adderall) and methylphenidate (e.g., Ritalin) are 
placed in Schedule II along with other psychotropic substances “whose 
liability to abuse constitutes a substantial risk to public health and which 
have little to moderate therapeutic usefulness.”70 The likelihood of abuse 
of Schedule III substances (e.g., various barbiturates such as amobarbital 
and pentobarbital, and the “date rape drug” flunitrazepam (“Rohypnol”)) 
constitute a “substantial risk to public health” with “moderate to great 
therapeutic usefulness.”71 Schedule IV drugs such as pemoline (Cylert), 
diazepam (Valium), and lorazepam (Ativan) are deemed to pose a “sig-
nificant risk to public health” and “a therapeutic usefulness from little to 
great.”72 
Under the 1971 Convention, the United States must, “with due regard 
to its constitutional provisions,” prohibit the advertisement of psycho-
tropic drugs to the general public.73 It must ensure that psychotropic 
drugs are used only for legitimate “medical and scientific” purposes74 in 
ways that do not “compromise individual and public health,”75 and make 
sure that psychotropic drugs are “supplied or dispensed for use by indi-
viduals pursuant to medical prescription only.”76 Furthermore, labels for 
these drugs must provide: “directions for use, including cautions and 
                                                                                                                                     
 68. WORLD HEALTH ORG., WHO EXPERT COMMITTEE ON DRUG DEPENDENCE: THIRTY- 
THIRD REPORT 1 (2003). 
 69. Id. at 3. 
 70. Id. 
 71. Id. 
 72. Id. 
 73. 1971 Convention, supra note 4, art. 10(2). 
 74. Id.  
 75. U.N. DRUG CONTROL PROGRAMME, AMPHETAMINE-TYPE STIMULANTS: A GLOBAL 
REVIEW 3 (1996), available at http://www.unodc.org/pdf/technical_series_1996-01-
01_1.pdf#search=%22amphetamine-type%20stimulants%20a%20global%20review%22. 
 76. 1971 Convention, supra note 4, art. 9(1). 
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warnings, . . . necessary for the safety of the user.”77 Prescriptions must 
be issued in accordance with “sound medical practice,”78 and the gov-
ernment must take “all practicable measures for the prevention of abuse 
of psychotropic substances.”79 
The nature of psychotropic drugs as a threat to public health and safety 
is echoed in the United Nations Convention on the Rights of the Child 
(“CRC”).80 This treaty, ratified by every recognized government except 
the United States,81 reflects the international community’s recognition 
that children are particularly deserving of protection from the potentially 
devastating effects of unwarranted exposure to psychotropic drugs. Al-
though it has not ratified the Convention, the United States has signed it, 
and, as such, commentators and courts have argued that the United States 
is obligated to uphold its provisions both under the Vienna Convention’s 
exhortation to refrain from doing anything that “would defeat the pur-
poses and objects” of a treaty signed but not ratified by a government,82 
as well as under customary international law.83 
The central motivating premise of the CRC is that “the best interests of 
the child shall be a primary consideration” in all actions undertaken by 
public and private institutions and governmental agents.84 In accordance 
with that principle, Article 33 of the CRC explicitly provides that gov-
ernments “shall take all appropriate measures, including legislative, ad-
ministrative, social[,] and educational measures, to protect children from 
the illicit use of . . . psychotropic substances as defined in the relevant 
international treaties.”85 Concomitantly, governments must “undertake to 
ensure the child such protection and care as is necessary” for the child’s 
well-being, and “ensure that the institutions, services[,] and facilities re-
sponsible for the care or protection of children . . . conform with the 
                                                                                                                                     
 77. Id. at art. 10(1). 
 78. Id. at art. 9(2). 
 79. Id. at art. 20. 
 80. Convention on the Rights of the Child, opened for signature Nov. 20, 1989, 1577 
U.N.T.S. 3. 
 81. See Christina Okereke, Note, The Abuse of Girls in U.S. Juvenile Detention Facil-
ities: Why the United States Should Ratify the Convention on the Rights of the Child and 
Establish a National Ombudsman for Children’s Rights, 30 FORDHAM INT’L L.J. 1709 
(2007). 
 82. Vienna Convention on the Law of Treaties art. 18, opened for signature May 23, 
1969, 1155 U.N.T.S. 331. 
 83. See Rebecca M. Stahl, Note, “Don’t Forget About Me”: Implementing Article 12 
of the United Nations Convention on the Rights of the Child, 24 ARIZ. J. INT’L & COMP. L. 
803, 811–12 (2007). 
 84. Convention on the Rights of the child, supra note 80, art. 2. 
 85. Id. at art. 33. 
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standards established by competent authorities, particularly in the areas 
of safety, health, in the number and suitability of their staff, as well as 
competent supervision.”86 
These principles embodied in the Convention on the Rights of the 
Child further illuminate the international community’s concern that 
children be protected from unwarranted exposure to psychotropic drugs. 
The overarching thrust of the 1971 Convention and the Rights of the 
Child is that governments should take all necessary measures to ensure 
that the public in general, and children in particular, are protected from 
the harmful effects of unregulated, medically unjustified uses of psycho-
tropic drugs. With this legal framework as the backdrop, the next part of 
this Article documents the shockingly high rates at which state-involved 
children are prescribed psychotropic drugs while exploring the connec-
tion between the overmedication of state-involved children and the U.S. 
government’s failure to aggressively regulate off-label prescription to 
children and direct-to-consumer advertising of psychotropic drugs. 
III. EPIDEMIC PSYCHOTROPIC DRUG PRESCRIBING TO UNITED STATES 
CHILDREN 
Although psychotropic drugs have long been used (illegitimately) to 
control problematic behaviors of children in juvenile prisons,87 psycho-
tropic drug prescriptions to state-involved children, as well as to children 
                                                                                                                                     
 86. Id. at art. 3. More generally, Article 19 of the CRC provides that children are to 
be protected from “all forms of physical or mental violence, injury or abuse, neglect or 
negligent treatment, maltreatment or exploitation, . . . while in the care of parent(s), legal 
guardian(s) or any other person who has the care of the child.” Id. at art.19. Additionally, 
children have the right to be free from economic exploitation, id. at art. 32, and from “all 
other forms of exploitation prejudicial to any aspects of the child’s welfare.” Id. at art. 36. 
Finally, Article 37 requires that “no child shall be subjected to torture or other cruel, in-
human or degrading treatment or punishment,” and that “every child deprived of liberty 
shall be treated with humanity and respect for the inherent dignity of the human person, 
and in a manner which takes into account the needs of persons of his or her age.” Id. at 
art. 37. 
 87. See, e.g., Nelson v. Heyne, 491 F.2d 352, 357 (7th Cir. 1974) (detailing abuses of 
psychotropic drugs in juvenile facilities and concluding that “the use of tranquilizing 
drugs as practiced by defendants constituted cruel and unusual punishment” in violation 
of the children’s rights under the 14th Amendment to the United States Constitution); 
Pena v. N.Y. State Div. for Youth, 419 F. Supp. 203, 204 (S.D.N.Y. 1976) (challenging 
the Goshen Annex for Boys, an institution within the New York State training school 
system, for its use of isolation, hand and feet restraints, and thorazine and other tranqui-
lizing drugs to control excited behavior of the children under the Eighth and Fourteenth 
Amendments); Drugs in Institutions: Hearings Before the Subcommittee to Investigate 
Juvenile Delinquency of the Senate Committee on the Judiciary, 94th Cong., 1st Sess. 2 
(1975) [hereinafter Drugs in Institutions]. 
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in the general public, have exploded since the 1990s.88 The following 
section details those astronomical increases and traces their evolution to 
the “Decade of the Brain,” during which time the federal government 
shifted the national focus from ecological factors in mental illness with 
an emphasis on psychosocial interventions to the biomedical view of 
mental illness as an organic brain disease best remediated with pharma-
ceuticals. 
A. Psychotropic Drugs Are Prescribed to State-Involved Children at 
Alarming Rates 
According to a widely-cited 2006 Brandeis University study, psycho-
tropic drug prescriptions for teenagers skyrocketed 250% between 1994 
and 2001.89 The Brandeis researchers found that the proportion of visits 
that resulted in psychotropic prescription rose from 3.4% in 1994–1995 
to 8.3% in 2000–2001, with the rate of such visits increasing 161.6% for 
youth ages fourteen to eighteen during that same period.90 Strikingly, 
they also found that the proportion of these visits associated with a men-
tal health diagnosis did not increase.91 In fact, during this same period, no 
psychiatric diagnosis was recorded for 14 to 26% of the youths who were 
prescribed a psychotropic medication.92 The authors concluded, some-
what diplomatically, that it was unclear whether the rapid increases in 
psychotropic drug prescriptions represented “a move toward greater 
access and more appropriate treatment or whether this represents an 
overreliance on medications.”93 
Some view the dramatic shift toward psychotropic drug use in children 
as an indication of “better case finding, better diagnosing, and a realiza-
tion that we do have active treatments that can benefit children.”94 How-
ever, some critics see the increasing proliferation of pediatric psycho-
                                                                                                                                     
 88. See generally Mark Olfson et al., National Trends in the Treatment of Attention 
Deficit Hyperactivity Disorder, 160 AM. J. OF PSYCHIATRY 1071 (2003); Mark Olfson et 
al., National Trends in the Use of Psychotropic Medications by Children, 41 J. AM. 
ACAD. CHILD & ADOLESCENT PSYCHIATRY 514 (2002); Julie M. Zito et al., Psychotropic 
Practice Patterns for Youth: A Ten Year Perspective, 157 ARCHIVES PEDIATRICS & 
ADOLESCENT MED. 17, 17 (2003). 
 89. See generally Cindy Parks Thomas et al., Trends in the Use of Psychotropic Me-
dications Among Adolescents, 1994 to 2001, 57 PSYCHIATRIC SERVICES 63 (2006). 
 90. Id. at 65–66. 
 91. Id. 
 92. Id. 
 93. Id. at 68. 
 94. An Interview with Marilyn Benoit, M.D., President of the American Academy of 
Child and Adolescent Psychiatry, STATE HEALTH LAWMAKERS’ DIG. (Nat’l Conference of 
State Legislatures, Washington, D.C.), Spring 2003. 
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pharmacology as evidence that psychotropic drugs are being used illegi-
timately under the guise of beneficial mental health treatment, to serve as 
a “chemical sledgehammer” to make state-involved children easier to 
manage.95 Indeed, evidence shows that children in state custody are par-
ticularly at risk of being prescribed psychotropic medications for prob-
lematic behaviors such as causing disturbances or acting out.96 Although 
poor record-keeping makes it difficult to accurately determine the exact 
magnitude of the practice, the predominance of psychopharmacology as 
the intervention of choice in responding to the psychological needs of 
state-involved children is well-documented.97 
For example, a 2001 report established that approximately 600 children 
who were enrolled in the Florida Medicaid system—most of which were 
in foster care and younger than age five—were prescribed drugs mar-
keted to treat schizophrenia, an illness very rarely diagnosed in children 
of that age.98 Jack Levine, then president of the Center for Florida’s 
Children, noted that 
[w]e make some basic assumptions about children who need medical 
care, assumptions about services that are supported by tax dollars, and 
especially about children who are in the care of state agencies. 
An assumption I thought we made was that their care would never 
be appreciably different, in terms of medical carefulness and appro-
priateness of prescriptions, than everyone else’s children.99 
Levine’s analysis suggested “a remarkable difference in how these 
children are being looked at, diagnosed, and treated,” and he went on to 
warn that he was “starting to get scared.”100 Similarly frightening find-
ings were made by the Texas Comptroller, Carole Strayhorn, who, in 
2004, issued a scathing report on the Texas foster care system, charging 
                                                                                                                                     
 95. David Crary, A Dilemma: Medications for Foster Kids, BOSTON.COM, Mar. 13, 
2007, http://www.boston.com/news/nation/articles/2007/03/13/a_dilemma_medications_ 
for_foster_kids/. 
 96. Id. (“[C]oast to coast, states are wrestling with how best to treat the legions of 
emotionally troubled foster kids in their care. Critics contend that powerful psychiatric 
drugs are overused and say poor record keeping masks the scope of the problem.”). 
 97. See Andrés Martin et al., Multiple Psychotropic Pharmacotherapy Among Child 
and Adolescent Enrollees in Connecticut Medicaid Managed Care, 54 PSYCHIATRIC 
SERVICES 72 (2003), available at http://psychservices.psychiatryonline.org/cgi/reprint/54/ 
1/72. 
 98. Carol Marbin Miller, Advocates Alarmed By Drugs Used for Kids: Medicaid 
Children Under 6 at Issue, MIAMI HERALD, May 7, 2001, available at http://www.vachss. 
com/help_text/archive/advocates_alarmed.html. 
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 100. Id. 
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that “astronomical amounts” of psychotropic medications were being 
dispensed to Texas foster children and that the Texas child welfare agen-
cy exercised “little meaningful oversight over these medications.”101 
Strayhorn found evidence that many Texas foster care children were ad-
ministered psychotropic drugs, not for legitimate medical purposes, but 
rather to generate more money for the child welfare agency and foster 
parents.102 
Other accounts of prescribing practices with respect to state-involved 
children include a University of Minnesota study showing that nearly 
35% of foster children in St. Louis County were receiving psychotropic 
medication compared with 15% of the general population,103 and a 2003 
report from the Florida Statewide Advocacy Council finding that over 
50% of the children enrolled in the Florida Medicaid program (approx-
imately 9,500) “had been treated with one or more psychotropic drugs in 
the year 2000.”104 The ages of the Florida children ranged from less than 
one to seventeen.105 Additionally, several investigative news reports in 
recent years attest to the sharp increase in prescriptions of psychotropic 
drugs to foster care children nationwide.106 
A similar pattern is evident in juvenile prisons across the country. For 
example, an April 2002 study by the Oregon Youth Authority (“OYA”) 
found that 81% of girls in Oregon’s juvenile correctional facilities met 
the requirements for a psychiatric diagnosis and 72% were taking psy-
                                                                                                                                     
 101. CAROLE KEETON STRAYHORN, TEX. COMPTROLLER OF PUB. ACCOUNTS, 
FORGOTTEN CHILDREN: A SPECIAL REPORT ON THE TEXAS FOSTER CARE SYSTEM 199 
(2004). 
 102. Id. 
 103. Hagen & Orbeck, supra note 12. 
 104. FLA. STATEWIDE ADVOCACY COUNCIL, supra note 62, at 4. The Florida study 
further documented that 44% of the children on psychotropic medications were not under 
the care of a physician, while others had no psychiatric diagnosis or had a diagnosis de-
scribed as “other.” Id. at 12, 13. Thirty-eight percent of the children studied were given 
drugs without a signed consent from a parent, guardian or judge, as state law requires. Id. 
at 17. Moreover, 89% of the children had no records in their file to show they were being 
medically monitored. Id. at 18. 
 105. Id. at 5. 
 106. See, e.g., Gary Craig, Potent Pills: More Foster Kids Getting Mood-Altering 
Drugs, DEMOCRAT & CHRONICLE, Dec. 9, 2007; Gary Craig, Issue Hasn’t Had Much 
Scrutiny in N.Y., DEMOCRAT & CHRONICLE, Dec. 10, 2007; Crary, supra note 95; Editori-
al, The Drugging of Foster Youth, S.F. CHRON., June 11, 2006 (noting that California 
does not attempt to keep track of how many foster youth are given psychotropic drugs, 
and that members of a state created Blue Ribbon Commission on Foster Care were caught 
off guard “when the overuse of psychotropic medications emerged as a major theme of 
foster youth talking about what is wrong with the system.”). 
2010] "THEY USE IT LIKE CANDY" 475 
chotropic medication.107 The report similarly documented that 54% of 
boys diagnosed with psychiatric conditions such as personality disorders 
and mental retardation were prescribed psychotropic drugs.108 A 2000 
survey of juvenile correctional facilities in Pennsylvania found that psy-
chotropic drugs were prescribed to as many as 40% to 50% of the child-
ren in some of the state’s juvenile prisons.109 Further, a 2004 report by 
the New Jersey Office of the Child Advocate detailing the conditions of 
juvenile confinement in New Jersey’s seventeen county juvenile deten-
tion centers revealed that, depending on the facility, anywhere from 10% 
to 50% of the children were taking psychotropic medications.110 
Low-income children are also particularly susceptible. Medicaid is a 
major source of funding for mental health and related support services 
for children, and, as of 2005, it covered 26% of U.S. children.111 In Tex-
as, the prevalence of anti-psychotic drugs in the population of children 
receiving benefits from the Texas Medicaid Program increased by 164% 
between 1996 and 2000 and the use of atypical antipsychotics112 in-
creased by 494% over the same period.113 A study of children and ado-
lescents in low- and moderate-income families who received medical 
care through TennCare (Tennessee’s managed care program for Medica-
id enrollees and the uninsured) revealed that the use of antipsychotic 
                                                                                                                                     
 107. OR. YOUTH AUTH., MENTAL HEALTH AND FEMALE OFFENDERS IN THE CUSTODY OF 
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 113. Nick C. Patel et al., Trends in Antipsychotic Use in a Texas Medicaid Population 
of Children and Adolescents: 1996 to 2000, 12 J. CHILD & ADOLESCENT PSYCHO- 
PHARMACOLOGY 221, 223 (2002). 
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drugs among low-income children nearly doubled between 1996 and 
2001.114 The percentage of psychotropic prescriptions to Tennessee’s 
poor children jumped by 61% among preschoolers, 93% among those 
age six to twelve, and 116% among children age thirteen to eighteen.115 
Consistent with statistics in other states, a study of Connecticut’s Medi-
caid managed care database concluded that the strongest predictor for 
whether a Connecticut child would be receiving psychotropic medica-
tions was state custody.116 
These staggering statistics beg the question whether the behaviors of 
state-involved children are sufficiently aberrant to warrant such apparent-
ly heavy-handed medication practices. While some argue that the huge 
increase in the use of psychotropic medications among children during 
the 1990s indicates a greater awareness of treatments—both within the 
medical industry and society at large—that can better children’s lives,117 
others describe the phenomenon as “child abuse on a grand scale.”118 As 
Thomas Grisso, a well-known expert in juvenile justice and pediatric 
forensic psychology has stressed, even “beneficent interventions unre-
strained can carry with them potential dangers to liberty and self-
determination,” including the “potential overuse of medications to 
achieve behavioral control” of children.119 
B. The 1990s: “Decade of the Brain” 
Studies have documented that pediatric psychopharmacotherapy in the 
United States increased dramatically during the late 1980s and through-
                                                                                                                                     
 114. William O. Cooper et al., New Users of Antipsychotic Medications Among Child-
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out the 1990s.120 Psychopharmacology rests on the premise that certain 
behaviors or psychological conditions are evidence of organic disease 
stemming from brain dysfunction and/or genetic abnormality that are 
most effectively treated with psychotropic drugs that chemically alter the 
brain.121 This understanding of psychiatric disorder or mental illness as 
biomedical “brain disease” marks a significant departure from previously 
dominant theories that recognize social-environmental factors as promi-
nent contributors to mental, emotional, and cognitive disturbances.122 
Historically, the biomedical view of mental disorder gained its strong-
hold in 1980 with the publication of the third edition of the American 
Psychiatric Association’s Diagnostic and Statistical Manual of Mental 
Disorders (“DSM-III”). Despite the lack of scientific proof for its under-
lying theory of brain dysfunction, the DSM-III, “with its symptom-based 
orientation . . . contributed significantly to a biological vision of mental 
health—which stresses the neurosciences, brain chemistry, and medica-
tions—superseding the psychosocial vision that had dominated for dec-
ades.”123 This new paradigm of mental illness “focused on the symptoms 
of mental disorders rather than their causes and emphasized pharmaco-
logical treatments over talk therapy and behavioral changes.” 124 
The United States government has played a central role in promoting 
the biomedical paradigm of mental disorder and the concomitant empha-
                                                                                                                                     
 120. See, e.g., Thomas et al., supra note 89, at 63–69 (2006) (finding that the propor-
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sis on drug intervention. The National Institute of Mental Health 
(“NIMH”), the government agency that finances and conducts research 
on mental illness, funded field trials of the DSM-III and “legitimiz[ed] 
the results by granting them the government’s seal of approval.”125 Gov-
ernment support for the brain disease vision of mental illness crystallized 
in 1989 with the designation by former President George Walker Bush of 
the 1990s as the “Decade of the Brain.” 126 In his official proclamation 
Bush asserted that “millions of Americans are affected each year by dis-
orders of the brain,” and declared that the goal of the initiative was two-
fold: to enhance “public awareness of the benefits to be derived from 
brain research,” and to focus government research on disorders and dis-
abilities that affect the brain.127 
In the aftermath of these developments, the NIMH de-emphasized 
funding for research into social, economic, and familial factors in mental 
disorders and prioritized research on brain dysfunction, genetics, and 
chemical imbalances.128 This intensified quest to promote the concept of 
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  Norbert Myslinki, a professor of pharmacology at the University of Maryland 
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mental illness as brain disease, fueled by an infusion of government 
funding,129 led to a shift in mental health treatment modalities toward 
primacy for drug therapies.130 Government support came to be weighted 
heavily toward research into neuropsychological processes—”mapping 
the brain’s biochemical circuitry”131—as an avenue for developing drugs 
to treat mental disorders.132 
More specifically, during the Decade of the Brain, the U.S. govern-
ment played a central role in promoting pediatric psychopharmacothera-
py.133 The federal government targeted the study of mental illness among 
children and adolescents as an explicit priority,134 and NIMH funding for 
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research in the field of child and adolescent psychiatry expanded dramat-
ically.135 The NIMH’s 1990 National Plan for Research on Child and 
Adolescent Mental Health Disorders clearly signaled the government’s 
new, biomedically-oriented direction. Although it acknowledged, in 
passing, the role of environment in children’s mental health issues, the 
National Plan firmly asserted that “[b]iology often sets the stage for 
trouble, as brain cells develop or function abnormally. We need to under-
stand how this happens and how to set things right.”136 The plan hig-
hlighted the shift to pharmacological interventions; for example, it 
claimed that NIMH funding for lithium had “helped millions of adults 
with manic-depressive illness, and it may have additional therapeutic 
payoff for many children and adolescents with mental disorders.”137 
Before the 1990s, prescription rates of psychotropic drugs to children 
in the general population were relatively low.138 However, it can be ar-
gued that the combination of the U.S. government’s increased emphasis 
on brain research, its support for prioritizing biomedical approaches to 
treatment of psychiatric conditions, and its targeted focus on children and 
adolescents all contributed significantly to the meteoric rise in the pre-
scription of psychotropic drugs to children since 1990, and to the rise 
among state-involved children in particular.139 In the words of noted 
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ADOLESCENT PSYCHOPHARMACOLOGY 221 (2002) (finding 160% increase in antipsychot-
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for the management of ADHD in the school setting increased approximately 250% from 
1990 to 1996); Zito et al., supra note 88, at 17–25 (observing a 200 to 300% increase in 
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Brandeis sociologist, Dr. Peter Conrad, “The 1990s may become known 
as the decade of psychotropic medication use in children.”140 
Along with its affirmative support for pediatric psychopharmacothera-
py, the United States government has further contributed to the excessive 
reliance on psychotropic drugs to respond to the mental health needs of 
state-involved children via its blatant refusal to comply with the 1971 
Convention’s explicit prohibition of direct-to-consumer (“DTC”) adver-
tising of psychotropic drugs. Researchers have noted the influential ef-
fect of advertising in encouraging increased acceptance of, and demand 
for, psychotropic drugs, particularly after the FDA relaxed its rules on 
prescription drug advertising at the height of the Decade of the Brain in 
1997.141 As described in the forthcoming part, the government’s failure 
to ban the advertising of controlled psychotropic drugs has rendered both 
the public and physicians more accepting of psychopharmaceutical inter-
vention as the primary response to children’s mental health issues, and, 
as a result, the health and safety of state-involved children has been sig-
nificantly undermined. 
IV. DIRECT-TO-CONSUMER ADVERTISING OF PSYCHOTROPIC DRUGS 
VIOLATES ARTICLE 10 OF THE 1971 CONVENTION ON PSYCHOTROPIC 
SUBSTANCES 
Along with its affirmative support for pediatric psychopharmacology 
(outlined in Part III above), the United States government has further 
promoted overprescription of psychotropic drugs to state-involved child-
ren by failing to comply with the 1971 Convention’s explicit prohibition 
on advertising of controlled psychotropic drugs directly to the public. 
Recognizing that the intended and inevitable result of advertising is to 
increase demand and consumption of psychotropic drugs—a result di-
ametrically opposed to the overarching goal of the 1971 Convention—
Article 10(2) provides that each party “shall, with due regard to its con-
stitutional provisions, prohibit the advertisement of [psychotropic] sub-
stances to the public.”142 Underscoring the convention’s public health 
protection principle, the WHO has taken the position that DTC advertis-
ing should not be allowed for any prescription drug, let alone for the 
                                                                                                                                     
prevalence of psychotropic drug use in children from 1987-1996 and that six percent of 
youth under 20 years of age were on psychotropic medications in 1996). 
 140. Peter Conrad, Editorial, Prescribing More Psychotropic Medications for Child-
ren: What Does the Increase Mean?, 158 ARCHIVES PEDIATRICS & ADOLESCENT MED 829 
(2004). 
 141. See, e.g., Thomas et al., supra note 89, at 68. 
 142. 1971 Convention, supra note 4, art. 10(2). 
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marketing of prescription drugs directed at children.143 There is virtually 
universal international compliance with the psychotropic drug advertis-
ing prohibition; most industrialized nations do ban DTC advertising for 
all prescription drugs.144 However, of the 183 signatories to the 1971 
Convention, only the United States and New Zealand do not have sta-
tutes in place to effectuate the DTC advertising provision—and the U.S. 
does not even ban advertising for those prescriptions that contain interna-
tionally scheduled psychotropic substances.145 
The advertising ban placed the onus on governments to prioritize pub-
lic health needs over drug companies’ profit-maximixing interests. The 
international agreement to prohibit DTC advertising of psychotropic 
drugs recognized the existence of an “inherent conflict of interest be-
tween the legitimate business goals of manufacturers and the social, 
medical, and economic needs of providers and the public to select and 
use drugs in the most rational way.”146 Nevertheless, concurrent with its 
intensive promotion of biological psychiatry during the 1990s, the United 
States government progressively liberalized key elements of existing 
drug advertising regulations, thereby enhancing the drug companies’ in-
fluence over public awareness, acceptance, and use of psychotropic 
drugs. As the following discussion demonstrates, the United States gov-
ernment has been complicit in elevating the commercial interests of the 
drug industry over the health and safety of children, effectively turning 
state-involved children into “cogs in the multi-million dollar pharmaceut-
ical industry machine.”147 
The United States has never banned advertising of prescription drugs. 
In 1938, as a result of a proliferation of advertisements for a variety of 
                                                                                                                                     
 143. WORLD HEALTH ORG., ETHICAL CRITERIA FOR MEDICINAL DRUG PROMOTION para. 
14 (1988) (citing criterion adopted at the 1988 World Health Assembly by consensus 
after discussion involving health workers, drug regulatory agencies, and consumers and 
industry representatives, and developed by WHO as part of its 1985 Revised Drug Strate-
gy); see also BARBARA MINTZES, HEALTH ACTION INT’L, BLURRING THE BOUNDARIES: 
NEW TRENDS IN DRUG PROMOTION (1998), available at http://www.haiweb.org/ 
pubs/blurring/blurring.intro.html [hereinafter BLURRING THE BOUNDARIES]. 
 144. See BARBARA MINTZES, HEALTH COUNCIL OF CANADA, WHAT ARE THE PUBLIC 
HEALTH IMPLICATIONS?: DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS IN 
CANADA 5 (2006), available at http://www.healthcouncilcanada.ca/docs/papers/2006/ 
hcc_dtc-advertising_200601_e_v6.pdf [hereinafter PUBLIC HEALTH IMPLICATIONS]. 
 145. Id. at 5. 
 146. BLURRING THE BOUNDARIES, supra note 143, at 1 (quoting World Health Org. 
[WHO], Clinical Pharmacological Evaluation in Drug Control, EUR/ICP/DSE 173 
(1993). 
 147. Susan McBride, Pharmaceutical Industry Practices and the Medicalisation of 
Childhood: Is Pathology for Sale?, 23 WINDSOR REV. LEGAL & SOC. ISSUES 55, 55 
(2007). 
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medicinal “cures,” the U.S. Congress enacted the Federal Food, Drug 
and Cosmetic Act (the “FFDCA”),148 which established the FDA, re-
quired that drugs be proven safe before they are advertised,149 and gave 
the FDA authority to consider drugs “misbranded” if their labeling or 
advertising is found to be misleading.150 A 1962 amendment to the 
FFDCA gave the FDA authority to regulate advertising of prescription 
drugs, and prohibited the agency from requiring prior approval of any 
such advertisement’s content.151 
The amendment did not craft any distinctions on the basis of an adver-
tisement’s audience—for instance, between professional and lay au-
diences152—and, prior to the 1980s, drug companies advertised prescrip-
tion drugs primarily in medical journals directed at physicians.153 How-
ever, in the early 1980s, drug companies began advertising directly to the 
public in magazines and newspapers.154 In response to constituents’ con-
cerns, the FDA asked for a voluntary moratorium on prescription drug 
advertising in 1983 to allow for public hearings and research on the sub-
ject.155 Two years later, while acknowledging “differences between 
healthcare professionals and consumers as recipients of drug promotion, 
such as differences in medical and pharmaceutical expertise, perception 
of pharmaceutical claims, and information processing,” the FDA with-
drew the moratorium without making any regulatory changes to account 
for those differences, stating that the existing regulations provided “suf-
ficient safeguards to protect consumers.”156 
Under the FFDCA and implementing FDA regulations, prescription 
drug ads must identify the product, its quantitative composition, and 
                                                                                                                                     
 148. Federal Food, Drug and Cosmetic Act, Pub. L. No. 75–717, 52 Stat. 1040 (1938) 
(codied as amended at 21 U.S.C. §§ 301–399(b) (2006)). 
 149. Ziad F. Gellad & Kenneth W. Lyles, Direct-to-Consumer Advertising of Pharma-
ceuticals, 120 AM. J. MED. 475, 475 (2007). 
 150. 21 U.S.C. § 321(n) (2006). 
 151. Drug Amendments of 1962, Pub. L. No. 87–781, sec. 131, § 502, 76 Stat. 780, 
791 (codified as amended at 21 U.S.C. 352(n) (2006)). 
 152. Prescription Drug Promotion: Hearing Before the S. Subcomm. on Consumer 
Affairs, Foreign Commerce, & Tourism, S.Comm. on Commerce, Science, & Transporta-
tion, 107th Cong. (2001) (statement of Nancy Ostrove, Deputy Director, Division of 
Drug Marketing, Advertising and Communications, Food & Drug Admin.), available at 
http://www.fda.gov/NewsEvents/Testimony/ucm115206.htm. 
 153. See Notice of Public Hearing and Request for Comments: Direct-to-Consumer 
Promotion, 60 Fed. Reg. 42,581, 42,582 (Aug. 16, 1995) [hereinafter 1995 Notice of 
Hearing]; DONNA VOGT, CONG. RESEARCH SERV., DIRECT-TO-CONSUMER ADVERTISING OF 
PRESCRIPTION DRUGS (2005). 
 154. See 1995 Notice of Hearing, supra note 153. 
 155. Id. at 42,582. 
 156. Id. 
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“other information in brief summary relating to side effects, contraindi-
cations, and effectiveness.”157 This “brief summary” provision mandates 
disclosure of all side effects, contraindications, and precautions on the 
product’s approved labeling.158 The requirement, which apparently antic-
ipated print advertisements only, is “generally fulfilled by including in 
the advertisement the sections of the approved labeling that discuss the 
product’s adverse event profile, contraindications, warnings, and precau-
tions.”159 Subsequent regulations added that product-claim broadcast ad-
vertisements160 must include “information relating to the most common 
side effects and contraindications in the audio or audio and visual parts 
of the advertisement,” and, importantly, rather than including every 
known risk of the drug, a product-claim broadcast advertisement could 
make “adequate provision” for the consumer to obtain the information 
through some other venue.161 However, before 1997 the FDA had not 
                                                                                                                                     
 157. Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 352(n) (2006); see also 21 
U.S.C. §§ 352(a), 321(n), 202.1(e) (2006) (providing that drugs are deemed to be “mi-
sbranded” if their labeling or advertising is false or misleading in any particular or fails to 
reveal material facts). 
 158. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CONSUMER-DIRECTED 
BROADCAST ADVERTISEMENTS 2 (1999), available at http://www.fda.gov/downloads/ 
RegulatoryInformation/Guidances/ 
ucm125064.pdf [hereinafter FDA GUIDANCE FOR INDUSTRY]. 
 159. 1995 Notice of Hearing, supra note 153, at 42,581. 
 160. See id. at 42,582 (recognizing three broad categories of DTC broadcast adver-
tisements: (1) product-claim ads identify a particular drug by name and make safety and 
efficacy claims about the drug; (2) help-seeking ads discuss a disease or condition and 
direct the consumer to “ask your doctor” for more information, but do not mention spe-
cific treatments or drugs; because help-seeking ads do not mention specific drug prod-
ucts, they are not subject to the Act or FDA regulations; and (3) reminder ads mention the 
name of the drug and other limited information, but does not make any representations or 
suggestions about the drug(s)); see also 21 C.F.R. § 202.1(e)(2) (2009) (describing prod-
uct claim ads and help seeking ads); FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR 
INDUSTRY: CONSUMER-DIRECTED BROADCAST ADVERTISEMENTS (1997) (explaining that, 
as of 1995, drug manufacturers primarily used reminder and help-seeking advertisements, 
which are exempt from the disclosure requirements). 
 161. 21 C.F.R. § 202.1(e)(1) (2008). 
All advertisements for any prescription drug . . . except [reminder advertise-
ments and help-seeking advertisements], shall present a true statement of in-
formation in brief summary relating to side effects, contraindications . . . and 
effectiveness. Advertisements broadcast through media such as radio, televi-
sion, or telephone communications systems shall include information relating 
to the major side effects and contraindications of the advertised drugs in the 
audio or audio and visual parts of the presentation and unless adequate provi-
sion is made for dissemination of the approved or permitted package labeling in 
2010] "THEY USE IT LIKE CANDY" 485 
issued any guidance for how the industry could satisfy the adequate pro-
vision alternative,162 and, given the costs of most commercial broadcast 
advertising, “to include this kind of detailed information in television 
and/or radio advertising was thought by the drug industry to be too cum-
bersome and expensive.”163 
With the Decade of the Brain in full swing, the FDA implemented a 
major policy in 1997 that “dramatically changed the playing field by al-
lowing the expansion of direct-to-consumer advertising into broadcast 
and electronic media.”164 The agency issued a Draft Guidance for Indus-
try (the “guidance”), which became final in 1999.165 This guidance made 
it much easier for drug companies to meet the requirement that broadcast 
advertisements contain extensive information about risks. It allowed drug 
companies to “omit detailed risk information (the ‘brief summary’) in 
broadcast full product ads if they stated a product’s major risks and pro-
vided specified means to obtain more complete risk information, includ-
ing toll-free phone numbers, websites, and print DTCA [direct-to-
consumer advertising of prescription drugs].”166 In the wake of the guid-
ance, spending on DTC advertising of prescription drugs rapidly in-
creased; today, it is a multi-billion dollar industry.167 
As this brief historical overview suggests, the U.S. government’s pro-
gressive relaxation of restrictions on prescription drug advertising has 
actively facilitated the Decade of the Brain goal of increasing public 
awareness regarding pharmaceutical interventions for mental health 
                                                                                                                                     
connection with the broadcast presentation shall contain a brief summary of all 
necessary information related to side effects and contraindications. 
Id. (Side effects and contraindications include among other things “side effects, warnings, 
precautions and contraindications.”). 
 162. Id. 
 163. VOGT, supra note 153, at 17. 
 164. Gelland & Lyles, supra note 149, at 476. 
 165. See FDA Notice of Draft Guidance for Industry: Consumer-Directed Broadcast 
Advertisements, 62 Fed. Reg. 43,171 (1997). 
 166. PUBLIC HEALTH IMPLICATIONS, supra note 144, at 14. 
 167. In 1991, the pharmaceutical industry spent roughly $55 million on DTC advertis-
ing. See Simon Gilbody et al., Editorial, Direct-to-Consumer Advertising of Psychotrop-
ics: An Emerging and Evolving Form of Pharmaceutical Influence, 185 BRIT. J. 
PSYCHIATRY 1 (2004). By 1996, DTC advertising of prescription drugs had risen to $791 
million, and by 2003 had quadrupled to $3.2 billion, and in 2005 reached $4.2 billion. See 
KAISER FAMILY FOUNDATION, PRESCRIPTION DRUG TRENDS 2 (2007), available at 
http://www.kff.org/rxdrugs/upload/3057_06.pdf; VOGT, supra note 153, at 3; see also 
U.S. GENERAL ACCOUNTABLITY OFFICE, PRESCRIPTION DRUGS: FDA OVERSIGHT OF 
DIRECT-TO-CONSUMER ADVERTISING HAS LIMITATIONS 1 (2002) (reporting that, as of 
2002, spending on DTC advertising of prescription drugs had tripled in recent years and 
that “DTC advertising appears to increase prescription drug spending and utilization.”). 
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problems. With that increased awareness has come greater acceptance 
and consumption of pharmaceuticals, not just by adults, but by children 
as well, all despite the significant risks involved.168 For example, me-
thylphenidate, the active ingredient in Ritalin, Concerta, and Metadate, is 
advertised directly to consumers and is the drug most commonly pre-
scribed to children diagnosed with ADHD.169 Methylphenidate, along 
with phencyclidine (commonly known as “PCP” or “angel dust”), is 
listed on Schedule II of the 1971 Convention’s “Green List”170 as a sub-
stance that “constitutes a substantial risk to public health” with “little to 
moderate therapeutic usefulness.”171 According to a 2009 National Insti-
tute of Drug Abuse (“NIDA”) funded study,172 methylphenidate has 
many similarities with cocaine, and “can have structural and biochemical 
effects in some regions of the brain that can be even greater than those of 
cocaine.”173 Commenting on the NIDA study, NIDA Director Dr. Nora 
Volkow observed that “non-medical use of methylphenidate and other 
stimulant medications can lead to addiction as well as a variety of other 
health consequences.”174 Dr. Volkow underscored the danger of uncriti-
cal acceptance of Ritalin and other stimulants touted in DTC ads, empha-
sizing the paucity of knowledge about “how methylphenidate affects the 
structure of and comunication between brain cells.”175 Not surprisingly, 
                                                                                                                                     
 168. See generally McBride, supra note 147. 
 169. See Matthew N. Strawn, Comment, Recent Developments in Direct Consumer 
Advertising of Attention Deficit Disorder Stimulants and Creating Limits to Withstand 
Constitutional Scrutiny, 19 J. CONTEMP. HEALTH L. & POL’Y 495 (2003). 
 170. GREEN LIST, supra note 30, at 5. 
 171. WORLD HEALTH ORG., WHO EXPERT COMMITTEE ON DRUG DEPENDENCE: 
SEVENTEENTH REPORT 14 (1970), available at http://whqlibdoc.who.int/trs/WHO_TRS_ 
437.pdf. 
 172. Yong Kim et al, Methylphenidate-Induced Dendritic Spine Formation and ΔFosB 
Expression in Nucleus Accumbens, 106 PROCEEDINGS NAT’L ACAD. SCI. U.S. 2915 
(2009). 
 173. Press Release, Nat’l Inst. of Health, U.S. Dep’t of Health & Human Serv., NIDA 
Study Shows That Methylphenidate (Ritalin) Causes Neuronal Changes in Brain Reward 
Areas: Similarities and Differences Compared to Cocaine were Found (Feb. 2, 2009), 
available at http://www.nih.gov/news/health/feb2009/nida-02.htm [hereinafter NIH Press 
Release]. But see Russell A. Barkley et al, Does the Treatment of Attention-
Deficit/Hyperactivity Disorder With Stimulants Contribute to Drug Use/Abuse? A 13-
Year Prospective Study, 111 PEDIATRICS 97, 97(2003) (finding “no compelling evidence” 
that stimulant treatment of children diagnosed with ADHD leads to an increased risk of 
substance experimentation, use, dependence, or abuse by adulthood). 
 174. NIH Press Release, supra note 173. 
 175. NIH Press Release, supra note 173. 
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the wisdom of dispensing methylphenidate to children remains highly 
controversial.176 
Researchers have pinpointed direct-to-consumer advertising of pre-
scription drugs as a key contributor to the explosive growth in the pre-
scribing of psychotropic drugs to children in the United States. One study 
that examined prescribing trends for adolescents between 1994 and 2001 
concluded that “direct-to-consumer advertising and other marketing 
strategies are key in encouraging greater use of psychotropics, particular-
ly for the increased use found after 1999.” 177 Notably, the FDA’s draft 
guidance, which liberalized prescription drug advertising, became final 
in 1999. 178 Soon after that, in 2001, advertisements for Adderall, Concer-
ta, and Ritalin began appearing in women’s magazines and on cable tele-
vision, which, according to one news reporter, marked “the first break 
from a 30-year old agreement between nations and the pharmaceutical 
industry not to market controlled drugs to consumers.”179 
The INCB has made clear that it considers the United States’ failure to 
prohibit DTC advertising of psychotropic drugs to be an egregious viola-
                                                                                                                                     
 176. NAT’L HEALTH INST., DIAGNOSIS AND TREATMENT OF ATTENTION DEFICIT 
HYPERACTIVITY DISORDER (1998), available at http://consensus.nih.gov/1998/1998 
AttentionDeficitHyperactivityDisorder110html.htm (“Despite progress in the assessment, 
diagnosis, and treatment of ADHD, this disorder and its treatment have remained contro-
versial, especially the use of psychostimulants for both short- and long-term treatment.”); 
see also Katherine Ellison, Brain Scans Link ADHD to Biological Flaw Tied to Motiva-
tion, WASH. POST, Sept. 22, 2009, http://www.washingtonpost.com/wp-dyn/content/ 
article/2009/09/21/AR2009092103100.html (“For decades, attention-deficit hyperactivity 
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social fabric? With 4.5 million U.S. children having received a diagnosis of the disord-
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 177. Thomas et. al., supra note 89, at 63-69 (“Advertisements for medications for 
ADHD, social phobia, and depression are now common in various public media. . . . 
Such drug industry promotion combined with the practice of detailing to physicians may 
affect both the public and physicians. Increasing numbers of patients come to physicians 
asking for particular medications, and drug industry detailing can promote off-label uses 
more aggressively. Surveys have suggested increasing pressure on physicians to prescribe 
drugs that they may or may not feel are medically warranted, and the most common rea-
son reported by physicians for inappropriate prescribing is patient demand.”). 
 178. FDA GUIDANCE FOR INDUSTRY, supra note 158. 
 179. Karen Thomas, Back to School for ADHD Drugs, USA TODAY, Aug. 28, 2001, at 
D1; see also Strawn, supra note 169, at 495 (“As parents prepared their children for the 
start of the 2001 school year, they were greeted for the first time with advertisements 
pitching behavior control drugs for their children. . . . This pushing of the advertising 
envelope for prescription stimulants, like Ritalin, is contrary to a thirty-year old interna-
tional agreement prohibiting the advertisement of such controlled substances.”). 
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tion of the 1971 Convention and a serious threat to public health. In its 
2000 annual report, the INCB noted that “[e]ffective but questionable 
sales promotion methods have often preceded increases in the consump-
tion of psychotropic substances,” and reiterated that governments should 
“strictly implement the provisions of article 10 of the 1971 Convention, 
which prohibits the advertisement of psychotropic substances to the gen-
eral public.”180 In its 2001 annual report, alarmed by reports that methyl-
phenidate was being “diverted for abuse by schoolchildren,” the INCB 
expressed concern about “legal loopholes in the United States that make 
possible public advertising of prescription drugs.”181 In a press release 
issued that year, the INCB noted that promotion to the public of psycho-
tropic drugs “frequently portrays drugs as common consumer goods,” 
and stressed that “the 1971 Convention on Psychotropic Substances pro-
hibits the advertisement of psychotropic substances to the general pub-
lic.”182 Reprimanding the United States for its longstanding failure to 
comply with the advertising ban, in its 2002 annual report the Board 
pointedly observed that “[a]dvertising through media in the United States 
reaches consumers not only in the United States, but also in other coun-
tries where such advertising is prohibited in line with article 10, para-
graph 2, of the 1971 Convention.”183 
The INCB has explicitly linked DTC advertising to the “over-
prescription of methylphenidate in the United States,” asserting that such 
over-prescription “may be the direct result of the direct-to-consumer ad-
vertising of that drug.”184 In its 2006 annual report, the INCB stated that 
“[a]ggressive promotion and advertising to the general public, in contra-
vention of the treaty obligations, may influence public perception about 
the availability of drugs on the unregulated market.”185 Succinctly captur-
ing the problematic effects of consumer advertising on children, the 
Board observed that public advertisement of controlled drugs used to 
treat ADD/ADHD “not only promotes their licit medical use and availa-
bility, but at the same time makes young people more aware of those 
drugs and thus more prone to illicitly consume them.”186 The Board ex-
pressed concern that public advertising of ADD/ADHD drugs “may send 
                                                                                                                                     
 180. INCB 2000 REPORT, supra note 6, at para. 22. 
 181. INCB 2001 REPORT, supra note 6, at para. 342. 
 182. Press Release, Int’l Narcotics Control Bd., Drug Taking Becoming Widespread 
Habit to Treat Social Problems, Warns UN Drug Control Body (Feb. 21, 2001), available 
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 183. INCB 2002 REPORT, supra note 6, at para. 175. 
 184. Id. 
 185. INCB 2006 REPORT, supra note 6, at para. 18. 
 186. Id. 
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the wrong signal about their real psychoactive and misuse potential.”187 
Most recently, in its 2008 annual report, the Board again criticized the 
United States, pointedly urging “the governments in which companies 
undertake direct-to-consumer advertising for drugs containing interna-
tionally controlled substances to adopt and implement regulations to ban 
such advertisements, in compliance with Article 10 of the 1971 Conven-
tion.”188 
While commentators vigorously debate the pros and cons of direct-to-
consumer advertising of prescription drugs,189 the essential question 
raised by the 1971 Convention’s advertising ban is the permissible scope 
of government regulation of such advertising under the United States 
Constitution’s limited protection for commercial speech.190 Although a 
thorough examination of that question is beyond the scope of this Article, 
it is conceivable that narrowly drawn legislation banning DTC advertis-
ing of internationally controlled psychotropic drugs could withstand a 
constitutional challenge.191 In any event, presumably with full knowledge 
of the United States’ constitutional free speech jurisprudence, the INCB 
remains steadfast and unequivocal, maintaining that the United States 
can and must comply with the 1971 Convention’s advertising ban. Un-
fortunately, the only enforcement mechanism available to the INCB to 
force compliance with the convention is its authority to “name and 
shame.”192 Thus, it is up to the United States government to take the in-
                                                                                                                                     
 187. Id. 
 188. INCB 2008 REPORT, supra note 6, at para. 69. 
 189. See, e.g., PETER R. BREGGIN & GINGER ROSS BREGGIN, THE WAR ON CHILDREN OF 
COLOR: PSYCHIATRY TARGETS INNER-CITY YOUTH (1998); McBride, supra note 147 (con-
tending that it contributes to the medicalization of childhood in particular.); Barbara 
Mintzes et al., Influence of Direct to Consumer Pharmaceutical Advertising and Patients’ 
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treatment options, and that the increased use of prescription drugs spurred by DTC adver-
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 190. See, e.g., Miriam Shuchman, Drug Risks and Free Speech—Can Congress Ban 
Consumer Drug Ads?, 356 NEW ENG. J. MED. 2236, 2236–2239 (2007). But see Jonathan 
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“puts advertising first and thereby undervalues the importance and complexity of gov-
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 191. See Strawn, supra note 169. 
 192. 1971 Convention, supra note 4, at art. 19. (describing the Board’s function as 
“quasi-judicial” in overseeing the implementation of the conventions. If the Board finds 
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itiative to fulfill its commitment under the 1971 Convention and imple-
ment legislation banning psychotropic drug advertisements. A ban on 
DTC advertising of psychotropic drugs in compliance with the 1971 
Convention would be a step in the right direction to begin to stem the 
growing tide of overmedication of state-involved children. 
V. THE PRESCRIPTION OF PSYCHOTROPIC DRUGS TO CHILDREN AS 
CURRENTLY PRACTICED IN THE UNITED STATES VIOLATES THE 1971 
CONVENTION’S “MEDICAL PURPOSES” RESTRICTION 
The United States government must fulfill its obligation under the 
1971 Convention to ensure that state-involved children are not prescribed 
psychotropic drugs without medical justification. Article 5 of the conven-
tion requires governments to limit, by appropriate measures, the use of 
drugs in Schedules II, III, and IV “to medical and scientific purposes.”193 
The following examination of criteria, developed by the INCB to guide 
its work in monitoring the implementation of the 1971 Convention, pro-
vides the framework for analyzing the legitimacy of the extensive off-
label prescription of psychotropic drugs to state-involved children in the 
United States. This analysis supports the conclusion that off-label pre-
scription of psychotropic drugs to children does not meet the internation-
al requirement that use of controlled psychotropic drugs be restricted to 
“medical purposes.” 
                                                                                                                                     
that the goals of the Convention “are being seriously endangered” by a country’s failure 
to implement its provisions, it may “ask for explanations from” the government in ques-
tion. The Board may call upon the Government “to adopt such remedial measures as shall 
seem under the circumstances to be necessary for the execution of the provisions” of the 
Convention, and, if satisfactory explanations are not forthcoming or the government fails 
to adopt remedial measures set out by the Board, the Board can call attention of the par-
ties, the Council and The Commission to the matter, and the party under scrutiny “shall 
be invited to be represented at a meeting of the Board at which a question directly inter-
esting it is considered.”). These measures basically come down to “naming and shaming” 
as the penalty for violations of the 1971 Convention. See generally Sandeep Gopalan, 
Alternative Sanctions and Social Norms in International Law: The Case of Abu Ghareib, 
2007 MICH. ST. L. REV. 785 (examining the role of shame and embarrassment in enforc-
ing international law). According to Gopalan, “[s]haming in the international law arena is 
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causing economic harm, shunning by other states and commercial entities, and mobiliz-
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 193. 1971 Convention, supra note 4, art. 5(2) (“Each Party shall . . . limit by such 
measures as it considers appropriate the manufacture, export, import, distribution and 
stocks of, trade in, and use and possession of, substances in Schedules II, III and IV to 
medical and scientific purposes.”). The convention restricts use of Schedule I substances 
to “scientific and very limited medical purposes.” Id. at art. 7(a) (emphasis added). 
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Noting that the terms “medical purposes” and “medical use” are used 
in, but not defined in, existing international drug control conventions, the 
INCB set out criteria to elucidate those expressions in its 2003 annual 
report.194 The INCB explained the term “medical purposes”—as used in 
Article 5 of the 1971 Convention—as a function of a drug’s “medical 
use”195 (that is, its usefulness in medical therapy).196 Legitimate medical 
uses for scheduled psychotropic drugs include “improving health and 
well-being” and “preventing and treating disease.”197 Because “efficacy 
and safety are basic conditions that have to be established before [a sche-
duled] drug can be marketed,”198 medical uses of psychotropic drugs 
“should be approved by the competent regulatory authority” of each 
country.199 In addition to efficacy and safety, the INCB considers “avail-
ability and cost and the knowledge and experience of those prescribing . . 
. and administering [the drug],”200 in order to establish compliance with 
the medical purposes requirement. Without sound evidence of therapeu-
tic value as measured by these criteria, the usefulness of a scheduled 
drug for medical purposes is significantly diminished; such lack of evi-
dence means the drugs “usefulness” becomes a subjective determination 
based solely on the drug’s “reputation for usefulness, which reflects the 
general opinion of practitioners or expert panels.”201 Moreover, even 
with FDA approval or a favorable reputation within the medical commu-
nity, the actual value of psychotropic drugs in addressing the problems 
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treating disease (including the alleviation of symptoms of that disease); (c) Acting as a 
diagnostic aid; (d) Aiding conception or providing contraception; (e) Providing general 
anaesthesia.”). 
 198. Id. at para. 231. 
 199. Id. at para. 234. In the United States, the Food and Drug Administration is the 
“competent regulatory authority” governing the approval for sale of prescription drugs, 
including internationally scheduled psychotropic drugs. U.S. Food & Drug Admin., 
Drugs, http://www.fda.gov/AboutFDA/Basics/ucm192696.htm. 
 200. INCB 2003 REPORT, supra note 6, at para. 230. 
 201. Id. 
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faced by state-involved children is substantially decreased where there 
are “safer alternatives for the same purposes.”202 
Assessed against these criteria, the conditions under which state-
involved children are typically prescribed psychotropic drugs fail alto-
gether to meet the 1971 Convention’s “medical purposes” requirement. 
As described in more detail below, the use of psychotropic drugs as 
chemical restraints to control disruptive or problematic behavior of child-
ren in foster care and in juvenile prisons is emphatically not a “medical 
purposes” use. Moreover, many contest the notion that state-involved 
children who are labeled with a psychiatric diagnosis are actually suffer-
ing from a “disease” for which drug treatment is appropriate or neces-
sary. This raises a legitimate concern because the majority of psycho-
tropic drugs are prescribed to children off-label, without the benefit of 
FDA-reviewed and approved evidence of safety and efficacy for pedia-
tric use. Finally, there is a notable lack of consensus among the medical 
community about the suitability of psychotropic drugs for pediatric use 
in light of the demonstrated and constantly emerging risks, uncertain 
benefits, and worrisome lack of knowledge about the long-term impact 
on children. Moreover, and perhaps most importantly, there are a wealth 
of safer alternatives for addressing the mental, behavioral, and emotional 
problems experienced by state-involved children. Given the serious prob-
lems associated with use of psychotropic drugs in children, it is urgent 
that the United States government take aggressive steps to comply with 
the 1971 Convention’s medical purposes requirement. 
A. Chemical Restraint is Not a “Medical Purpose” 
The deliberate use of psychotropic medications to control nonconform-
ing or problematic behavior of state-involved children for the conveni-
ence of others obviously violates the 1971 Convention’s medical purpos-
es requirement. According to the American Association of Child and 
Adolescent Psychiatry (“AACAP”), “chemical restraint” of a child is the 
use of a drug without a therapeutic purpose, but for the sole purpose of 
sedating and immobilizing the child.203 Chemical restraint of children has 
                                                                                                                                     
 202. INCB 2000 REPORT, supra note 6, at para. 2 (observing that “in the absence of 
perfect alternatives, many less than ideal . . . psychotropic substances continue to be used 
today as pharmaceuticals for the treatment of diseases and the alleviation of pain and 
other forms of human suffering. Their actual value in medicine always depends on the 
availability of safer alternatives for the same purposes.”). 
 203. AMERICAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, RECOMMENDATIONS 
FOR JUVENILE JUSTICE REFORM 70 (2d ed. 2005) [hereinafter JUVENILE JUSTICE REFORM 
RECOMMENDATIONS], available at http://www.aacap.org/galleries/PracticeInformation/ 
JJmonograph1005.pdf ( “Some juvenile justice systems use chemical restraint. . . . Chem-
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been roundly condemned by the AACAP, the Child Welfare League, and 
Amnesty International.204 Despite the fact that there is virtually no re-
search to support the use of psychotropics on children for such condi-
tions as “acute aggression,”205 state-involved children are sometimes giv-
en these powerful, brain-altering chemicals simply for being aggressive, 
unruly, or otherwise problematic.206 
Juvenile prison staff members are often given authority to forcibly in-
ject children with psychotropic drugs on an “as needed” (“p.r.n”) basis 
“simply to stop the current aggressive outburst” of a child.207 United 
States Department of Justice (“DOJ”) investigative letters reporting on 
conditions in juvenile prisons across the country have noted the routine 
use of psychotropic medications by juvenile prison staffs to restrain, pu-
nish, and sedate incarcerated children—sometimes simply for annoying 
behavior.208 For example, federal investigators found that children in a 
                                                                                                                                     
ical restraint is defined as using a medication without a therapeutic purpose, but for the 
sole purpose of sedation and . . . immobilizing the patient.”); see also THE ALLIANCE TO 
PREVENT RESTRAINT, AVERSIVE INTERVENTIONS, AND SECLUSION, IN THE NAME OF 
TREATMENT: A PARENT’S GUIDE TO PROTECTING YOUR CHILD FROM RESTRAINT, 
AVERSIVE INTERVENTIONS, AND SECLUSION 4 (2005), available at http://www.tash.org/ 
publications/inthenameoftreatment.pdf. 
 204. JUVENILE JUSTICE REFORM RECOMMENDATIONS, supra note 203, at 70. 
 205. Grisso, supra note 51, at 91. 
 206. See generally BREGGIN & BREGGIN, supra note 189, at 65–86. Breggin notes that 
the DSM-III-R states that children diagnosed as suffering from “disruptive behavior dis-
orders” are “characterized by behavior that is socially disruptive and is often more dis-
tressing to others than to the people with the disorders.” Id. at 67. The Breggins observe 
that the “‘illness’ consists of being disruptive to the lives of adults—a definition that 
seems tailored for social control.” Id. 
 207. GRISSO, supra note 51, at 90–91. This problem has been noted in other confine-
ment contexts as well. See, e.g., Kathleen Auerhahn & Elizabeth Dermody Leonard, Do-
cile Bodies? Chemical Restraints and the Female Inmate, 90 J. CRIM. L. & CRIMINOLOGY 
599, 604 (2000) (describing use of psychotropic medication as disciplinary tool in pris-
ons, and that “the narratives [the inmates] present . . . deomonstrate [that] jail and prison 
inmates in the United States are frequently medicated without diagnosis or proper psy-
chiatric and physical assessments”); see also 42 C.F.R. § 483.13(a) (2009) (residents in 
long-term care facilities have “the right to be free from any physical or chemical re-
straints imposed for purposes of discipline or convenience, and not required to treat the 
resident’s medical symptoms.”). 
 208. See, e.g., Letter from Bill Lan Lee, Acting Assistant Att’y Gen., U.S. Dep’t of 
Justice, to Zell Miller, Governor, State of Georgia n. 5 (Feb. 13, 1998), available at 
http://www.justice.gov/crt/split/documents/gajuvfind.php [hereinafter Georgia Findings 
Letter] (stating that “[u]ntil recently, staff were also authorized to use medication—in the 
form of involuntary injections of psychotropic drugs—to restrain youths deemed out-of-
control, on the authority of a ‘PRN’ (as needed) prescription by a psychiatrist and admi-
nistered by the facility nursing staff.”). Similarly, a 2004 Department of Justice investiga-
tion into conditions at the Charles H. Hickey, Jr. School in Baltimore, Maryland found 
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Georgia facility “were subject to forced injections [of psychotropic 
drugs] as punishment for angering staff nurses, rather than as an appro-
priately monitored medical treatment to prevent injury to the youths or 
others.”209 The investigators emphasized that the practice of giving juve-
nile prison staffs unrestrained authority to give psychotropic drugs to 
children on an “as needed” basis “is subject to dangerous abuses in a cor-
rectional setting.”210 
Similar misuse of psychotropic drugs in the foster care setting is well-
documented.211 For example, a physician reviewing the medication 
records of children in the Texas foster care system found sparse support 
for the aggressive use of psychotropic medications discovered there. The 
report questioned whether the children had behaved in ways “sufficiently 
aberrant to warrant these medication practices,” and wondered whether 
the children had simply been “‘medicated’ into compliance for home 
expectations.”212 The report alleged that some foster care parents sought 
out medication for children in their care not only to make them more 
                                                                                                                                     
that psychotropic medication decisions appeared to be “directed at behavior control rather 
than improved functioning, a practice that represents a substantial departure from gener-
ally accepted standards of treatment.” Letter from R. Alexander Acosta, Assistant Att’y 
Gen., U.S. Dep’t of Justice, to Robert L. Ehrlich, Jr., Governor, State of Maryland 27 
(Apr. 9, 2004), available at http://www.justice.gov/crt/split/documents/cheltenham_md. 
pdf. The investigators found that “youth are often prescribed sleep medications with little 
justification. These medications are often administered late in the afternoon, thus unne-
cessarily sedating youth early, making them less able to participate in evening programs.” 
Id. at 28. A 2007 report found that staff at the Marion Juvenile Correctional Facility in 
Marion, Ohio, used four-point restraints, bed restraints and forced medications to manage 
severely mentally ill youth. Letter from Wan J. Kim, Assistant Att’y Gen., U.S. Dep’t of 
Justice, to Ted Strickland, Governor, State of Ohio 12 (May 9, 2007), available at 
http://www.justice.gov/crt/split/documents/marion_findlet_5-9-07.pdf. 
 209. Georgia Findings Letter, supra note 208, at n5. 
 210. Id. 
 211. See sources cited supra note 106; Potent Pills: More Foster Kids Getting Mood-
Altering Drugs, DEMOCRAT & CHRONICLE, Dec. 9, 2007 (investigating psychotropic drug 
use amongst New York foster children and questioning whether sharp increase in such 
use is “because they have so many needs” or whether drugs are “used more as a conve-
nient way to straitjacket troublesome behavior”); Crary, supra note 95 (summarizing 
concerns about overmedication of foster children in Florida, Texas, California, and New 
York, and reporting that “[s]ome parents and advocacy groups say child welfare authori-
ties routinely resort to drugs to pacify foster children without fully considering non-
medication options”); Carol Marbin Miller, 1 in 4 Foster Kids on Risky Mind Medication, 
MIAMI HERALD, Jan. 15, 2005, at 1A (noting evidence that some children in the care of 
the Florida Department of Children and Families are prescribed psychotropic medications 
simply to address behavioral problems). 
 212. STRAYHORN, supra note 101, at 204. 
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submissive during care, but, more nefariously, to get more money in pub-
lic benefits.213 
State-involved children are not only vulnerable to the misuse of psy-
chotropic drugs for the purpose of behavior control; they are also at high 
risk of being wrongly diagnosed with a mental illness for which medica-
tion is then prescribed.214 As compared to children in the general popula-
tion, children in foster care and juvenile justice systems are disproportio-
nately exposed to a variety of risk factors that may negatively impact 
their mental, emotional, and cognitive development, and which may lead 
to acting out behaviors and emotional disturbances.215 Premature birth, 
prenatal drug and alcohol exposure, parents with mental illness or sub-
stance abuse problems, exposure to high levels of violence in their homes 
or communities, child maltreatment, and poverty are all risk factors that 
may contribute to acting out behaviors and cognitive, mental, and emo-
tional difficulties. 216 The medicalization of these problems “is likely to 
result in frequent misdiagnosis—labeling of behavioral problems that 
result from interpersonal difficulties, realistic feelings that are not exces-
sive or out of proportion to the child’s real life experiences, or reactions 
to current life stresses as major psychiatric disorders needing possibly 
unnecessary medical treatment.”217 
                                                                                                                                     
 213. Id. at 199 (survey comments expressing concern that Texas foster children were 
“medicated for higher-level ratings [more money for agency and parents] instead of as-
sisting foster parents in making these kids good citizens” and that children “were given 
astronomical amounts of medication. Diagnoses were altered to accommodate hallucina-
tion[s] which may have been induced by overmedication.”). 
 214. As Comptroller Carole Strayhorn astutely observed in Forgotten Children: 
Many foster children have psychological problems and are being treated with 
an array of medications to manage their symptoms. But even fundamentally 
normal children who have been taken from their homes and families can be-
come aggressive and “emotionally reactive” due to a lost sense of trust and 
their conditions are only worsened by multiple placements and frequent case-
worker turnover. As their feelings of instability increase, their emotions may 
erupt, and their caretakers then are, in the words of one child psychiatrist, “just 
chasing an untreatable problem with more medication. 
STRAYHORN, supra note 101, at 199. 
 215. See, e.g., Naylor et al., supra note 15 at 176. 
 216. Martin Irwin, Use of Psychiatric Medication in Foster Care Children in Onondaga 
County 1 (2002), (unpublished manuscript, on file with the author); TEX. DEP’T OF ST. 
HEALTH SERV., PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR FOSTER 
CHILDREN [hereinafter FOSTER CHILD MEDICATION PARAMETERS], available at 
http://www.dshs.state.tx.us/mhprograms/pdf/PsychotropicMedicationUtilizationParamete
rsFosterChildren.pdf. 
 217. Irwin, supra note 216, at 1. Irwin stresses that foster children’s expressions of 
“unhappiness, sadness, worry and anger,” which are appropriate and understandable res-
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The use of psychotropic drugs to control nonconforming behavior of 
children is not a new phenomenon in the United States. For example, in 
1975, the United States Senate heard testimony describing the “chemical 
straitjacketing” of thousands of children within the juvenile justice sys-
tem and in other institutions.218 The use of psychotropic drugs to chemi-
cally restrain state-involved children without medical justification clearly 
violates the medical purposes requirement of the 1971 Convention, and 
damages rather than improves the health and well-being of children who 
are subjected to this horrendous and illegal practice. The United States 
government must comply with its obligation under the 1971 Convention 
and put an end to this long-standing and egregious abuse of state-
involved children. 
B. Contesting the Characterization of Childhood Behavior as “Disease” 
A fundamental pre-condition of legitimate medicinal use of a sche-
duled psychotropic drug under the 1971 Convention is the presence of 
“disease.”219 Whether the widespread use of psychotropic drugs to ad-
dress problematic behaviors exhibited by state-involved children consti-
tutes a legitimate medical purpose under the 1971 Convention is highly 
questionable. The trend toward medicalization of child behavior can be 
seen as a key factor contributing to the increasing prescription of psycho-
tropic drugs to state-involved children in the United States. 
Medicalization of social problems has been described as “a process by 
which nonmedical problems become defined and treated as medical 
problems.”220 Undergirding the contemporary expression of this process 
                                                                                                                                     
ponses to the reality of their lives “can easily be confused with depression, anxiety or 
bipolar disorder, ADHD or conduct disorder.” Id.; see also FOSTER CHILD MEDICATION 
PARAMETERS, supra note 216 at 2 (noting that foster children “often present with a fluidi-
ty of different symptoms over time reflective of past traumatic and reactive attachment 
difficulties that may mimic many overlapping psychiatric disorders. Establishment of 
rapport is often difficult. These multiple factors serve to complicate diagnosis.”). 
 218. Drugs in Institutions, supra note 87. The inappropriate use of psychotropic drugs 
as chemical restraints has been noted in other confinement contexts. See, e.g., Auerhahn 
& Leonard, supra note 207, at 604 (describing use of psychotropic medication as discip-
linary tools in prisons, and observing that “jail and prison inmates in the United States are 
frequently medicated without diagnosis or proper psychiatric and physical assessments”); 
see also 42 C.F.R. § 483.13(a) (2009) (“The [nursing home] resident has the right to be 
free from any physical or chemical restraints imposed for purposes of discipline or con-
venience, and not required to treat the resident’s medical symptoms.”). 
 219. INCB 2003 REPORT, supra note 6, at para. 233. 
 220. PETER CONRAD, THE MEDICALIZATION OF SOCIETY: ON THE TRANSFORMATION OF 
HUMAN CONDITIONS INTO TREATABLE DISORDERS 5 (2007). Conrad elaborates: 
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is the idea that a broad array of mental, emotional, and behavioral ma-
nifestations are the result of chemical imbalances in the brain and that the 
right pill will correct this imbalance and make the problems go away.221 
The INCB has repeatedly expressed concern about the use of psychotrop-
ic drugs in the United States to address typical childhood behaviors and 
social difficulties. For example, in a 1996 press release, the INCB hig-
hlighted concerns expressed in its 1995 annual report about “the unprec-
edented sharp increase” in the “controversially extensive use” of methyl-
phenidate in treating ADD in children.222 The Board noted concerns that 
doctors prescribing methylphenidate might be “too often overlooking 
other causes for attention and behaviour problems” and “opting for an 
‘easy’ solution for behavioral problems that may have complex caus-
es.”223 The following year, the INCB said that abuse of amphetamine-
type stimulants such as methylphenidate had reached “epidemic propor-
tions,” and stressed that “despite the warning issued a year ago, the issue 
still requires serious attention.224 Observing that ADD is “a syndrome 
largely manifested in behavioral patterns” with the primary signs being 
“inattention, impulsivity, and, in some cases, hyperactivity,” the INCB 
took special note of warnings about the highly subjective nature of “par-
ents’ and teachers’ assessments of what constitutes ‘inattention’ and ‘im-
pulsivity.’”225 
Dr. Hamid Ghodse, the immediate past president of the INCB, has de-
nounced the “liberal use of a drug with the specific intention of modify-
ing a child’s behavior such that he or she becomes more compliant and 
                                                                                                                                     
The key to medicalization is definition. That is, a problem is defined in medical 
terms, described using medical language, understood through the adoption of a 
medical framework, or “treated” with a medical intervention. Thus, we can ex-
amine the medicalization of epilepsy, a disorder most people would agree is 
“really” medical, as well as we can examine the medicalization of alcoholism, 
or ADHD, menopause, or erectile dysfunction. While “medicalize” literally 
means “to make medical,” . . . the main point in considering medicalization is 
that an entity that is regarded as an illness or disease is not ipso facto a medical 
problem; rather, it needs to become defined as one. 
Id. 
 221. See generally Mayes & Horwitz, supra note 121. 
 222. Press Release, United Nations Information Service, Dramatic Increase in Methyl-
phenidate Consumption in US: Marketing Methods Questioned (Feb. 28, 1996), available 
at http://www.incb.org/pdf/e/press/1995/e_bn_02.pdf. 
 223. Id. 
 224. International Narcotics Control Board, supra note 6. 
 225. Id. 
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less troublesome.”226 Dr. Ghodse has asserted that children in the United 
States “who are prescribed drugs for attention-deficit hyperactivity dis-
order (ADHD) are often not ill,” and believes that “[w]e are medicalising 
something that is often not a medical condition,” and that psychotropic 
drugs are too often “used to counter social problems, sometimes without 
solid medical justification.” 227 
Indeed, the editors of the Diagnostic and Statistical Manual of Mental 
Disorders (“DSM-IV”)228 themselves admit that the manual describes 
diagnoses “strictly in terms of patterns of [behavioral] symptoms that 
tend to cluster together. These symptoms can be observed by the clini-
cian or reported by the patient or family members.”229 The American 
Academy of Pediatrics (“AAP”) has noted that “the specification of be-
havior items, number of items, and level of impairment” required for a 
DSM-IV diagnosis of ADHD are simply reflections of “the current con-
sensus among clinicians, particularly psychiatry.”230 The AAP emphasiz-
es that “[d]espite the agreement of many professionals working in this 
field, the DSM-IV criteria [for ADHD] remain a consensus without clear 
empirical data . . . . [T]he behavioral characteristics specified in DSM-IV, 
despite efforts to standardize them, remain subjective and may be inter-
preted differently by different observers.”231 
Given the deep uncertainties surrounding the origins of symptomatic 
patterns exhibited by those labeled with a psychiatric diagnosis, the lack 
of empirical support is unsurprising. In fact, the DSM-IV editors candid-
ly acknowledge that “there is no objective marker that can identify a 
large majority of mental disorders; diagnosis is a judgment call based on 
an interview and/or observation of behavior.”232 Acknowledging that 
                                                                                                                                     
 226. Psychotropic Drugs are Overprescribed in the West, According to UN Official, 
REUTERS HEALTH, June 24, 2002, available at http://www.vachss.com/help_text/archive/ 
drugs_overprescribed.html (reporting on speech by Dr. Ghodse at 2002 annual meeting 
of the Royal College of Psychiatrists in London). 
 227. Id. 
 228. AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS (DSM-IV) (4th ed. 2006). 
 229. American Psychiatric Association, What Is the DSM and What Is It Used For?, 
http://www.psych.org/MainMenu/Research/DSMIV/FAQs/WhatistheDSMandwhatisituse
dfor.aspx (last visited Jan. 1, 2010). 
 230. Committee on Quality Improvement Subcommittee on Attention-
deficit/hyperactivity Disorder, American Academy of Pediatrics, Clinical Practice 
Guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity 
Disorder, 105 PEDIATRICS 1158, 1160 (2000), available at http://aappolicy.aappub 
lications.org/cgi/content/full/pediatrics;105/5/1158. 
 231. Id. at 1162–63. 
 232. Albee, supra note 130, at 638. 
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“the cause of most mental disorders is currently unknown and subject to 
much speculation,” they caution that 
[p]atients sharing the same diagnostic label do not necessarily have dis-
turbances that share the same etiology nor would they necessarily re-
spond to the same treatment. It is therefore critical to understand that 
the diagnostic terms and categories in the DSM represent only current 
knowledge about how symptoms cluster together. We fully expect that, 
over the coming decades, the DSM system will be radically reorganized 
as the etiologies of mental disorders become better understood.233 
Nevertheless, various professional associations actively promote the 
view that mental disturbances are organic in nature. For example, while 
asserting that mental disorders represent “dysfunctions of the highest 
integrative functions of the human brain including cognition, or thought; 
emotional regulation; and executive function, or the ability of the brain to 
plan and organize behavior,” the American Psychiatric Association ac-
knowledges that “brain science has not advanced to the point where 
scientists or clinicians can point to readily discernible pathologic lesions 
or genetic abnormalities that in and of themselves serve as reliable or 
predictive biomarkers of a given mental disorder or mental disorders as a 
group.”234 The American Association for Marriage and Family Therapy 
flatly states on its website that “[m]ental illnesses are biologically based, 
meaning that chemicals or structures in the brain are not working as they 
are supposed to, resulting in symptoms that cannot be managed or over-
come without treatment, often resulting in lives that are unstable and un-
fulfilled.”235 The website goes on to state that “[d]ue to the biological 
basis of [childhood onset mental illness or ‘COMI’], psychiatric evalua-
tion and treatment is generally necessary. The disorders associated with 
COMI usually require medications for symptom management.”236 
                                                                                                                                     
 233. American Psychiatric Association, supra note 229. 
 234. Press Release, American Psychiatric Association, American Psychiatric Associa-
tion Statement on Diagnosis and Treatment of Mental Disorders (Sept. 25 2003), availa-
ble at http://www.psych.org/MainMenu/Newsroom/NewsReleases/2003NewsReleases/ 
mentaldisorders0339.aspx [hereinafter APA Press Release]. 
 235. American Association of Marriage and Family Therapists, AAMFT Consumer 
Update: Mental Illness in Children, http://www.aamft.org/families/Consumer_Updates/ 
MentalIllnessinChildren.asp. 
 236. Id. For two interesting articles refuting the mental illness as biological brain dis-
ease paradigm, see George W. Albee & Justin M. Joffe, Mental Illness is NOT “an Ill-
ness Like Any Other”, 24 J. PRIMARY PREVENTION 419 (2004) and Fred Baughman, There 
Is No Such Thing as a Psychiatric Disorder/Disease/Chemical Imbalance, 3 PLOS 
MEDICINE 1189, 1189 July 2006, available at http://www.plosmedicine.org/article/ 
info:doi%2F10.1371%2Fjournal.pmed.0030318. 
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These pronouncements are remarkable in light of the fact that the idea 
that there is irrefutable scientific evidence that mental illness is biologi-
cally based was soundly refuted by a panel of experts convened in 1998 
by the National Institutes of Mental Health to study Attention Deficit 
Hyperactivity Disorder (“ADHD”).237 The panel explicitly confirmed 
that there exists no evidence to establish ADHD, or any other psychiatric 
disorder, as a brain disease. “After years of clinical research and expe-
rience with ADHD,” the panel reported, “our knowledge about the cause 
or causes of ADHD remains largely speculative.”238 Further, such a lack 
of scientific evidence “is not unique to ADHD, but applies as well to 
most psychiatric disorders, including disabling diseases such as schi-
zophrenia.”239 Thus, the conclusion that a child is suffering from a psy-
chiatric disorder or mental illness is not based on biological or physio-
logical measures, but on normative value judgments and subjective cha-
racterizations of the child’s behavior.240 As explained by one physician, 
there are 
no specific blood tests, brain scans, or any other procedure guaranteed 
to give us an unequivocal answer to any given child’s “real” problem. 
Instead, we must rely on what we see and hear during clinical visits and 
learn from taking a history to try to fit each child into the right diagnos-
tic box, and the definition of who belongs in each box can change over 
time.241 
                                                                                                                                     
 237. NAT’L INST. OF HEALTH, supra note 176. 
 238. Id.; see also BREGGIN & BREGGIN, supra note 189, at 53–55 (highlighting lack of 
proof for claims that mental illness is biomedically or genetically based); Albee & Joffe, 
supra note 236. 
 239. See NAT’L INST. OF HEALTH, supra note 176; see also ELLIOTT & KELLY, supra 
note 23, at 59 (“The fact that there is no definitive test for ADHD or other disruptive 
disorders further complicates the situation. The behaviors that we use to define these 
disorders are by no means specific to the disorder—they can arise from a variety of con-
ditions or even represent normative behavior.”). 
 240. See, e.g., Baughman, supra note 236 (arguing that “[i]f there is a macroscopic, 
microscopic, or chemical abnormality, a disease is present. Nowhere in the brains or bo-
dies of children said to have ADHD or any other psychiatric diagnosis has a disord-
er/disease been confirmed.”); see also APA Press Release, supra note 234 (rejecting the 
critique that “the lack of a diagnostic laboratory test capable of confirming the presence 
of a mental disorder constituted evidence that these disorders are not medically valid 
conditions,” but nevertheless acknowledging that “[i]n the absence of one or more bio-
logical markers for mental disorders, these conditions are defined by a variety of con-
cepts,” including “the distress experienced and reported by a person who has a mental 
disorder; the level of disability associated with a particular condition; patterns of beha-
vior; and statistical deviation from population-based norms for cognitive processes, mood 
regulation, or other indices of thought, emotion, and behavior.”). 
 241. ELLIOTT & KELLY, supra note 26, at 16. 
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If state-involved children are given psychotropic drugs on the premise 
that the drugs have medicinal value in the treatment of disease, it would 
arguably be necessary to demonstrate with sound evidence that the child-
ren are indeed suffering from a medical disease or illness.242 To the ex-
tent that behavioral problems exhibited by state-involved children are 
largely the result of predictable and normal reactions to the stresses from 
their life experiences and are not evidence of medical disease or illness, 
“treatment” of these behaviors with psychotropic drugs is glaringly in-
consistent with the medical purposes requirement set out in Article 5 of 
the 1971 Convention. 
C. Treating Children with Psychotropic Drugs “Off-Label”: “Legitimate 
Medical Use”? 
Under Article 10 of the 1971 Convention, the United States govern-
ment must “require . . . such directions for use, including cautions and 
warnings, to be indicated on the labels where practicable and in any case 
on the accompanying leaflet of retail packages of psychotropic sub-
stances, as in its opinion are necessary for the safety of the user.”243 
However, the overwhelming majority of psychotropic drugs prescribed 
to children are prescribed “off-label,” meaning that they have not been 
approved by the FDA for pediatric use. Consequently, their labels do not 
provide child-specific instructions for use or cautions or warnings neces-
sary to ensure the safety of the children taking them. 
                                                                                                                                     
 242. BROWN & SAWYER, supra note 3, at 14 (noting that use of medication for the 
management of behavioral problems in classroom settings for diagnostic entities, particu-
larly ADHD, are more often based on insufficient normative data rather than on any solid 
scientific basis). Indeed, several years before the NIH Consensus Statement, Peter Breg-
gin similarly observed: 
There are some real diseases that produce brain damage and mental dysfunc-
tion. The defects can be genetic, as in a limited number of cases of Alzheimer’s 
disease, in some forms of mental retardation, such as Down’s syndrome, and in 
dementing disorders such as Huntington’s chorea. In each case there is a gene-
ralized impairment of the brain, resulting in measurable losses of mental func-
tion, such as short-term memory, calculating, and abstract reasoning. These 
losses can be detected in clinical interview and often they can be roughly quan-
tified on neuropsychological testing. But even in severe psychiatric disorders, 
such as “schizophrenia” or “manic-depressive disorder,” brain function is not 
impaired, and no biological cause has been discovered . . . often the individual 
is functioning at a superior level of intelligence and mental ability. 
BREGGIN & BREGGIN, supra note 189, at 54. 
 243. 1971 Convention, supra note 4, art. 10(1). 
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In its role as the “competent regulatory authority” of the United States 
government,244 the Food and Drug Administration approves prescription 
drugs for sale and marketing.245 Approval is granted only if the human 
studies conducted by the drug company support a drug’s safe and effec-
tive use by the tested populations.246 As part of the approval process, 
manufacturers are required to submit proposed labeling, which must con-
tain “a summary of essential scientific information needed for the safe 
and effective use of the drug,” including the product’s intended use—for 
example, the conditions it treats, the appropriate patient population, ad-
ministration and dosage information, and contraindications, warnings, 
and precautions.247 “Contraindication” describes “situations in which the 
drug should not be used because the risk of use . . . clearly outweighs any 
possible therapeutic benefit.”248 “Warnings and precautions” describe 
“clinically significant adverse reactions . . . , other potential safety ha-
zards . . . , limitations in use imposed by them . . . , and steps that should 
be taken if they occur,” and any other “information regarding any special 
care to be exercised by the practitioner for safe and effective use of the 
drug.”249 
                                                                                                                                     
 244. See INCB 2003 REPORT, supra note 6, at para. 234. 
 245. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355 (2006). See generally 21 
C.F.R. §§ 314.50, 314.100–314.170 (2009). 
 246. See 21 C.F.R. § 314.2 (2009); Althea Gregory, Denying Protection to Those Most 
in Need: The FDA’s Unconstitutional Treatment of Children, 8 ALB. L. J. SCI. & TECH. 
121, 126–27 (describing in detail the FDA’s drug approval process). It is important to 
note that, in reporting the usefulness or potential benefits of psychopharmacotherapies for 
psychiatric disorders or their symptoms, researchers distinguish between efficacy and 
effectiveness of a particular treatment. As Grisso explains, in research into the efficacy of 
a psychopharmacological treatment, study patients are “selected according to rigorous 
specifications to ensure that they have the disorder for which the method is intended to be 
of benefit,” and the psychotropic medication is employed “under highly controlled condi-
tions.” GRISSO, supra note 51, at 87. Grisso further notes: 
Efficacy is expressed as the proportion of patients in the experimental group, 
compared to the proportion of patients in the control group, who demonstrate a 
specific beneficial outcome (as measured with standardized instruments). In 
contrast, a method’s effectiveness refers to its value in the real world where re-
searchers cannot control the quality of its application. . . . [T]he effectiveness of 
a method of therapy refers to its value when ordinary clinicians in actual clini-
cal settings provide it to whatever patients obtain their services. 
Id. 
 247. 21 C.F.R. § 201.56 (2009). 
 248. 21 C.F.R. §§ 201.56(b)(1), 201.57(c)(5) (2009). 
 249. 21 C.F.R. § 201.57(c)(6)(i)–(ii). 
2010] "THEY USE IT LIKE CANDY" 503 
The most common use of “off-label” prescription occurs when drugs 
approved for the treatment of adults are prescribed to treat children.250 In 
the United States, “approximately 45% of medications used for the 
treatment of emotional or behavioral disturbances in children are [pre-
scribed] off-label, [with] no approved use, medical or psychiatric, for 
patients under 18.”251 Additionally, only about one-third of psychotropic 
drugs are approved for psychiatric treatment of children; some of them, 
such as divalproex sodium (Depakote) and clonidine, “are approved for 
the treatment of specific medical illnesses in patients less than 18 years 
of age, but not for the treatment of psychiatric disorders.”252 Thus, most 
psychotropic drugs prescribed to children do not carry child-specific 
labeling information.253 
Accurate labeling information is crucial to the safety and well-being of 
state-involved children who are prescribed psychotropic drugs. Prescrip-
tion drug labels or packet inserts are “intended to provide all of the in-
formation judged to be necessary for the drug or biological to be used 
safely and effectively for the approved indication(s).”254 However, doc-
tors routinely prescribe psychotropic drugs to state-involved children 
without any clinically-tested proof that they are safe or effective for use 
in children, and with little or no label information to guide their decision-
making as to if and how to use them.255 Thus, the United States govern-
ment’s failure to require child-specific labeling of psychotropic drugs in 
compliance with the 1971 Convention’s regulatory agency approval not 
                                                                                                                                     
 250. See Charles J. Cote et al., Is the “Therapeutic Orphan” About to be Adopted?, 98 
PEDIATRICS 118, 122 (1996). 
 251. Health Care of Children in Foster Care: Hearing Before the Subcomm. on In-
come Security and Family Support of the H. Comm. on Ways & Means, 110th Cong., 1st 
Sess. (2007) (statement of Michael Naylor, Director, Division of Child and Adolescent 
Psychiatry, Program Institute for Juvenile Research, University of Illinois-Chicago) [he-
reinafter Naylor Testimony]. As of 2007, the United States Government Accountability 
Office estimated that only about one-third of all prescription drugs prescribed to children 
have been studied and labeled for pediatric use. See U.S GOV’T ACCOUNTABILITY OFFICE, 
PEDIATRIC DRUG RESEARCH: STUDIES CONDUCTED UNDER BEST PHARMACEUTICALS FOR 
CHILDREN ACT 1 (2007), available at http://www.gao.gov/new.items/d07557.pdf [herei-
nafter BPCA REPORT]. 
 252. Naylor Testimony, supra note 251 (emphasis added). 
 253. Committee on Drugs, American Academy of Pediatrics, Use of Drugs Not De-
scribed in the Package Insert (Off-Label Uses), 110 PEDIATRICS 181 (2002). 
 254. Id. 
 255. See Psychotropic Medication Patterns, supra note 12. Dr. Zito’s study of psycho-
tropic drug prescribing to youth in foster care noted “the prominent [off-label] use of 
patent-protected, expensive psychotropic medications” such as sertraline and escitalo-
pram, which “comprised 74% of SSRI use in the study month, although neither drug has a 
labeled indication for the treatment of depression in children and adolescents.” Id. at 161. 
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only violates the convention’s medical purposes requirement, but more 
importantly, puts hundreds of thousands of children at grave risk of harm 
from exposure to powerful and addictive psychotropic drugs. 
Off-label prescribing, even of controlled substances, is not illegal, and 
the FDA does not regulate the practice.256 The standard for off-label pre-
scribing of FDA-endorsed drugs is minimal; physicians may use FDA 
approved drugs “in whatever way they deem beneficial, as long as there 
is some evidence that it could be helpful.”257 Particularly with respect to 
psychotropic drugs under international control, the FDA’s permissive 
stance seems untenable, given that the off-label use of psychotropic me-
dications in children is “plagued with uncertainties about genuine effica-
cy and safety.”258 
Although there are laws designed to induce pharmaceutical companies 
to gather information about the safety and efficacy of their products in 
children, and to provide the same dosing and risk information as is re-
quired for adults, most psychotropic drugs commonly prescribed to state-
involved children still do not contain this information.259 However, while 
these laws have somewhat increased the number of prescription drugs 
that provide child-specific dosing and risk information, they have not, for 
the most part, resulted in psychotropic drug labeling changes sufficient to 
provide prescribers and parents with necessary use and risk informa-
                                                                                                                                     
 256. See 21 U.S.C. § 396 (2006) (“Nothing in this chapter shall be construed to limit or 
interfere with the authority of a health care practitioner to prescribe or administer any 
legally marketed device to a patient for any condition or disease within a legitimate 
health care practitioner-patient relationship.”). 
 257. ELLIOTT & KELLY, supra note 26, at 23. 
 258. Id. Using the example of how anticonvulsants approved by the FDA for control-
ling epileptic seizures in adults came to be widely used for treating bipolar disorder in 
children, Dr. Elliot explains that if a physician concludes that a medication seems to help 
with a condition for which the FDA has not given its approval, “the clinician may publish 
what is called a case report, or may simply tell colleagues, who pass it on to other col-
leagues. Word spreads, and others begin using it. Inevitably, it starts being used in child-
ren and adolescents too . . . . This type of work, often just clinical reports based on a few 
patients, is much simpler, faster, and far cheaper than what the FDA requires.” Id. 
 259. See Best Pharmaceuticals for Children Act of 2007, Pub. L. No. 110-85, 121 Stat. 
876 (codified as amended in scattered sections of 21 U.S.C. and 42 U.S.C.) (providing 
financial incentives to pharmaceutical companies for pediatric testing of on-patent drugs, 
a process for the study of off-patent drugs, a safety review of all drugs granted pediatric 
exclusivity, and the public dissemination of information from pediatric studies con-
ducted); Pediatric Research Equity Act of 2007, Pub. L. No. 110-85, 121 Stat. 866 (codi-
fied as amended in 21 U.S.C. § 355c (2006)) (codifying the authority of the FDA to re-
quire pediatric studies of certain drugs and biological agents.); Food and Drug Adminis-
tration Modernization Act of 1997, Pub. L. No. 105–115, sec. 111, § 505A, 111 Stat. 
2296 (codified as amended at 21 U.S.C. § 355a (2006)). 
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tion.260 Given the well-founded concerns about the safety of psychotropic 
drugs, particularly the long-term risks to children’s developing brains,261 
the United States’ continued failure to require regulatory approval for 
pediatric use of psychotropic drugs and appropriate child-specific labe-
ling in contravention of the the 1971 Convention is egregious. 
D. Safer Alternatives to Psychotropic Drug Therapy Are Available 
A thorough assessment of the legitimacy of psychotropic drug use for 
state-involved children under the 1971 Convention requires a considera-
tion of the availability of safer alternatives for addressing each child’s 
presenting issues. The INCB stresses that the actual value of a scheduled 
psychotropic drug for medical purposes “always depends on the availa-
bility of safer alternatives for the same purposes.”262 Addressing this very 
issue, a comprehensive study examining the evidence base of psycho-
pharmacological and psychosocial interventions for childhood disorders 
released in 2006 by the American Psychological Association (the 
“APA”) stated that “[t]he preponderance of available evidence indicates 
that psychosocial treatments are safer than psychoactive medications.”263 
Indeed, experts agree that most children and teenagers suffering from 
psychological problems do not require psychiatric medication; instead, as 
recommended by the APA Working Group, best practices indicate that 
                                                                                                                                     
 260. See BPCA REPORT, supra note 251; see also Joseph Deveaugh-Geiss et al., Child 
and Adolescent Psychopharmacology in the New Millennium: A Workshop for Academia, 
Industry, and Government, J. AM. ACAD. CHILD & ADOLESCENT PSYCHIATRY 261, 264 
(2006) (stating that “despite the many studies generated by the FDAMA [Food and Drug 
Administration Modernization Act], only about one third of drugs used in children have 
pediatric prescribing information in the product label. In psychopharmacology, of the 12 
products granted exclusivity, the studies resulted in additional indications for just four 
products: sertraline for pediatric obsessive-compulsive disorder, and Adderrall XR, Con-
certa, and atomoxetine for adolescent ADHD. The latter three were already intended for 
use in childhood ADHD, and the labeling was simply expanded to include use in adoles-
cents. . . . [O]therwise, exclusivity studies of psychopharmacological agents have, for the 
most part, resulted in labeling language noting that clinical studies did not support a pe-
diatric indication.”). 
 261. See, e.g., Daryl Efron et al., Prescribing of Psychotropic Medications for Child-
ren by Australian Pediatricians and Child Psychiatrists, 111 PEDIATRICS 372, 373 
(2003), available at http://pediatrics.aappublications.org/cgi/reprint/111/2/372 (noting 
that “for many psychotropic medications it is not clear that the benefits outweigh the 
potential harms in children. Potential long-term effects are of concern, particularly given 
the increasing understanding of the susceptibility of the developing brain, biochemically 
and even microstructurally, to environmental influences.”). 
 262. INCB 2000 REPORT, supra note 6, at para. 2. 
 263. WORKING GROUP ON PSYCHOACTIVE MEDICATIONS FOR CHILDREN AND 
ADOLESCENTS, supra note 41. 
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psychosocial interventions, most often involving the family, as well as 
the individual, can be effective in addressing children’s problems.264 
Even in regard to those childhood conditions that are judged to be largely 
neurobiological in nature and responsive to medication treatments, most 
experts agree that medication should never be the sole treatment.265 
There are a host of evidence-based approaches available to address 
children’s mental health needs, including: cognitive behavioral therapy, 
assertiveness training, problem-solving skills training, traditional patient-
therapist relationships, peer group therapy, functional family therapy, 
multi-systemic therapy, and systems therapy, to name a few.266 As noted 
child mental health expert Dr. Thomas Grisso explains, there are a range 
of approaches to children’s mental health that do not rely on drugs: 
At one end of this spectrum is any mode of treatment primarily involv-
ing a therapist and a patient in conversation, for any theoretical or prac-
tical reason, focused on changing the patient’s behavior, thinking, or 
emotional condition. At the other end is an intervention that seeks these 
changes by altering the environmental circumstances in which the pa-
tient is expected to function in everyday life. Midway along this spec-
trum are a variety of methods that involve direct work with the patient 
in the context of people and social systems that are important in the pa-
tient’s life.267 
Also taking note of the link between excessive and exclusive reliance 
on pharmacological treatment of mental disorders and psychiatric condi-
tions and overconsumption of psychotropic drugs, the INCB has ob-
served that “[t]here is a wide range of complementary or alternative 
treatment approaches for many of the mental disorders and painful condi-
tions treated today with pharmaceuticals (psychotherapy, counseling, 
traditional medicine), and such alternatives may often be culturally more 
relevant and more effective.”268 
Nevertheless, despite the existence of these safer alternatives that may 
improve children’s daily functioning without the serious risks associated 
with psychotropic drugs, treatment with psychotropic medication is the 
                                                                                                                                     
 264. JOHN PRESTON ET AL., CHILD AND ADOLESCENT CLINICAL PSYCHOPHARMACOLOGY 
MADE SIMPLE 2 (2d ed. 2010). 
 265. Id. FOSTER CHILD MEDICATION PARAMETERS, supra note 216, at 3 (observing that 
“[g]iven the unusual stress and change in environmental circumstances associated with 
being a foster child, counseling or psychotherapy should generally begin before or con-
current with prescription of a psychotropic medication.”). 
 266. GRISSO, supra note 51, at 84–85; see also ELLIOTT & KELLY, supra note 26, at 
227–39 (describing psychotherapies, natural treatments, and somatic treatments). 
 267. GRISSO, supra note 51, at 84–85. 
 268. INCB 2000 REPORT, supra note 6, at para. 28. 
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only treatment considered and implemented for dealing with the proble-
matic behavior of large numbers of children in foster care and juvenile 
prisons. The availability of nondrug alternatives that rely on interperson-
al relationships and support for the youth, his or her family, community, 
and the systems in which he or she operates substantially undermine the 
notion that administration of psychotropic drugs to children serves a “le-
gitimate medical use” under the 1971 Convention, especially given the 
well-documented risks and lack of scientific evidence of their safety and 
efficacy.269 
For all the above reasons—concerns about the validity of classifying 
childhood behaviors as disease; the availability of less harmful and po-
tentially more beneficial therapies to address children’s emotional, beha-
vioral, and cognitive difficulties; and the virtually complete absence of 
scientific proof of the efficacy and safety of their use for childhood dis-
orders—pediatric psychopharmacotherapy as commonly practiced in the 
United States does not satisfy the 1971 Convention’s requirement that 
psychotropic drugs be strictly limited to use for “medical purposes.” 
VI. PSYCHOTROPIC DRUGS ARE NOT PRESCRIBED TO CHILDREN IN 
STATE CUSTODY IN ACCORDANCE WITH SOUND MEDICAL PRACTICE 
Article 9 of the 1971 Convention imposes another requirement, distinct 
from, but integral to the “medical purposes” requirement of Article 5. 
Article 9 requires the United States government to ensure that psycho-
tropic drugs are prescribed “in accordance with sound medical practice 
and subject to such regulation . . . as will protect the public health and 
welfare.”270 To ensure compliance with the sound medical practice re-
quirement, the INCB insists that governments establish national stan-
dards for prescribing and administering psychotropic drugs.271 In the 
United States, a number of professional organizations have published 
                                                                                                                                     
 269. See, e.g., R. Elliott Ingersoll et al., Children and Psychotropic Medication: What 
Role Should Advocacy Counseling Play?, 82 J. COUNSELING & DEV. 337 (2004); Lidia 
Wasowicz, Ped Med: Non-Drug Options Slighted?, UPI.COM, July 16, 2007, http:// 
www.upi.com/Consumer_Health_Daily/Reports/2007/07/16/ped_med_nondrug_options_
slighted/6725/. 
 270. 1971 Convention, supra note 4, art. 9(2) (“The Parties shall take measures to 
ensure that prescriptions for substances in Schedules II, III and IV are issued in accor-
dance with sound medical practice and subject to such regulation, particularly as to the 
number of times they may be refilled and the duration of their validity, as will protect the 
public health and welfare.”). 
 271. INCB 1998 REPORT, supra note 6, at para. 32 (“National health authorities should 
implement drug control measures and ensure that good prescribing and dispensing prac-
tices are established and followed and that patients are provided with complete and cor-
rect information.”). 
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best practices guides for the use of psychotropic drugs in state-involved 
children,272 and increasing numbers of states have enacted legislation 
and/or agency level guidelines aimed at setting standards and guidelines 
for monitoring psychotropic drug prescriptions for state-involved child-
ren.273 However, despite the growing recognition of the urgent need for 
close control and monitoring of psychotropic drug prescriptions to state-
involved children, to date, the federal government has not set national, 
uniform standards to ensure that they are prescribed and administered to 
state-involved children only for medical purposes and in accordance with 
sound medical practice. In the absence of such legislation, state-involved 
children are routinely subjected to egregious and flagrant violations of 
their right under the 1971 Convention to be free from illegitimate expo-
sure to psychotropic drugs 
The United States government itself has documented many of these 
abuses in juvenile prisons across the country. Pursuant to its authority 
under the Civil Rights of Institutionalized Persons Act of 1980 (CRIPA), 
the Attorney General investigates institutional conditions and may file 
lawsuits to remedy a pattern or practice of unlawful conditions unco-
vered.274 The Attorney General is also authorized, under the Violent 
                                                                                                                                     
 272. See, e.g., AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, supra 
note 15; LISA HUNTER ROMANELLI ET AL., ANNIE E. CASEY FOUNDATION, MENTAL 
HEALTH PRACTICES IN CHILD WELFARE GUIDELINES TOOLKIT (2009), available at 
http://www.casey.org/Resources/Publications/pdf/MentalHealthPractices.pdf; PETER J. 
JENSEN ET AL., ANNIE E. CASEY FOUNDATION, MENTAL HEALTH PRACTICE GUIDELINES 
FOR CHILD WELFARE (2009); NAT’L COMM’N ON CORR. HEALTH CARE, STANDARDS FOR 
HEALTH SERVICES IN JUVENILE DETENTION AND CONFINEMENT FACILITIES (2004); Ameri-
can Academy of Child and Adolescent Psychiatry, Practice Parameter for the Assess-
ment and Treatment of Youth in Juvenile Detention and Correctional Facilities, 44 J. AM. 
ACAD. CHILD & ADOLESCENT PSYCHIATRY 1085 (2005). 
 273. See Naylor et al., supra note 15, at 181 (the authors provide a table summarizing 
psychotropic medication consent procedures by state); see also Informational Letter from 
Office of Strategic Planning & Policy Dev., N.Y. State Office of Children and Family 
Serv., to Commissioners of Social Services et al. (Feb. 13, 2008), available at 
http://www.ocfs.state.ny.us/main/sppd/health_services/manual.asp (regarding The Use of 
Psychiatric Medications for Children and Youth in Placement: Authority to Consent to 
Medical Care). 
 274. In pertinent part, the Civil Rights of Institutionalized Persons Act provides that 
[w]henever the Attorney General has reasonable cause to believe that any State 
or political subdivision of a State, official, employee, or agent thereof, or other 
person acting on behalf of a State or political subdivision of a State is subject-
ing persons residing in or confined to an institution . . . to egregious or flagrant 
conditions which deprive such persons of any rights, privileges, or immunities 
secured or protected by the Constitution or laws of the United States causing 
such persons to suffer grievous harm, and that such deprivation is pursuant to a 
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Crime Control and Law Enforcement Act of 1994, to sue administrators 
of juvenile justice systems where there is a pattern or practice of violat-
ing incarcerated juveniles’ federal statutory and constitutional rights.275 
Over the years, pursuant to the Attorney General’s authority under these 
laws, investigations by the Special Litigation Section (the “SLS”)276 of 
the United States Department of Justice, Civil Rights Division have 
called attention to numerous flagrant and dangerous departures from 
generally accepted medical practices in almost every area relating to the 
prescription and administration of psychotropic drugs in juvenile prisons 
across the country. The DOJ has documented a frightening array of sub- 
standard practices and substantial departures from generally accepted 
medical practices that not only constitute serious violations of children’s 
constitutional rights, but, as the following analysis will demonstrate, also 
contravene the 1971 Convention’s mandate that the government ensure 
that sound medical practices are followed in the prescription and admin-
istration of controlled psychotropic drugs. 
Children in juvenile prisons are subjected to substantial departures 
from sound medical practices in almost every area of psychotropic drug 
administration. For example, DOJ investigations have documented fail-
                                                                                                                                     
pattern or practice of resistance to the full enjoyment of such rights, privileges, 
or immunities, the Attorney General, for or in the name of the United States, 
may institute a civil action in any appropriate United States district court 
against such party . . . . 
Civil Rights of Institutionalized Persons Act, Pub. L. No. 96–247, 94 Stat. 349, § 3(a) 
(1980) (codified at 42 U.S.C. § 1997–1997j). 
 275. Federal Civil Rights Statutes, 42 U.S.C. § 14141 (2006) (making it unlawful “for 
any governmental authority, or any agent thereof, or any person acting on behalf of a 
governmental authority, to engage in a pattern or practice of conduct by law enforcement 
officers or by officials or employees of any governmental agency with responsibility for 
the administration of juvenile justice or the incarceration of juveniles that deprives per-
sons of rights, privileges, or immunities secured or protected by the Constitution or laws 
of the United States,” and providing that “[w]henever the Attorney General has reasona-
ble cause to believe that a violation of paragraph (1) has occurred, the Attorney General, 
for or in the name of the United States, may in a civil action obtain appropriate equitable 
and declaratory relief to eliminate the pattern or practice”). 
 276. The Special Litigation Section of the Civil Rights Division “protects the constitu-
tional and federal statutory rights of persons confined in certain institutions owned or 
operated by, or on behalf of, state or local governments,” including “facilities for individ-
uals who are mentally ill and developmentally disabled, nursing homes, juvenile correc-
tional facilities, and adult jails and prisons.” Press Release, Dep’t of Justice, Fact Sheet: 
Department of Justice Efforts to Protect the Rights of Servicemembers and Veterans 
(May 23, 2008), available at http://www.justice.gov/opa/pr/2008/May/08-crt-462.html. 
510 BROOK. J. INT’L L. [Vol. 35:2 
ures to follow proper psychiatric diagnostic procedures,277 and adminis-
tration of psychotropic drugs to children by staff untrained in psychiatric 
diagnosis or psychopharmacology.278 The failure to gain informed con-
sent or court authorization for psychotropic drug treatment is perva-
sive,279 and drugs are commonly used as the sole intervention for child-
ren’s mental health problems, without any attempts to integrate appropri-
ate psychotherapy or other types of counseling.280 Documentation sup-
porting the use of medications and medical charting is often incomplete 
or missing altogether,281 and close monitoring of the effectiveness of pre-
                                                                                                                                     
 277. See, e.g., Letter from Loretta King, Acting Assistant Att’y Gen., U.S. Dep’t of 
Justice, to David A. Patterson, Governor, State of New York 17 (Aug. 14, 2009), availa-
ble at http://www.justice.gov/crt/split/documents/NY_juvenile_facilities_findlet_08-14-
2009.pdf [hereinafter New York Findings Letter] (finding that the majority of psychiatric 
evaluations at juvenile facilities “did not come close to meeting the criteria” for profes-
sional standards of care for youth in juvenile detention facilities; “[t]he evaluations typi-
cally lacked basic, necessary information, including justification for the diagnosis and 
evidence of prior record review. As a consequence, the treatment of youth with serious 
mental illness was based on poor information and was generally ineffective.”). 
 278. See, e.g., Letter from R. Alexander Acosta, Assistant Att’y Gen., U.S. Dep’t of 
Justice, to Jennifer M. Granholm, Governor, State of Michigan 14–15 (Apr. 19, 2004), 
available at http://www.justice.gov/crt/split/documents/granholm_findinglet.pdf [herei-
nafter Michigan Findings Letter] (observing that the facility used “non-medical staff to 
dispense medications. Given that the staff have no training in pharmacology, side effect 
recognition, psychological aspects of medication compliance, or symptom management, 
this practice places both the youth and the facility at great risk. . . . We observed several 
occasions where medical personnel took it upon themselves to dispense especially dan-
gerous medications.”). 
 279. See, e.g., id. at 14 n.3 (noting that the facility “lack[ed] a formal policy regarding 
youth and/or parental consent to medication. Staff gave various answers when asked 
about the facility’s practice regarding consent, evidencing the absence of a consistent 
practice.”). 
 280. See, e.g., Georgia Findings Letter, supra note 208 (observing that the contract 
psychiatrist, who was not a specialist in child and adolescent psychiatry, spent his time 
“solely monitoring psychotropic medications, meeting with youths on medications for 
brief (five- to fifteen-minute) interviews once a month” and “[v]ery few youths in any of 
the[] facilities receive[d] any significant psychotherapy, skilled mental health counseling 
or behavior management”); Michigan Findings Letter, supra note 278, at 13 (observing 
that the facility “fail[ed] to treat adequately youths with severe mental illnesses, lacks 
important protocols for psychotropic medication, and does not provide treatment plan-
ning tailored to the needs of the individuals with mental illness”). 
 281. See, e.g., Michigan Findings Letter, supra note 278, at 12–13 (“Neither the psy-
chiatrists, who prescribe a range of psychotropic medications, nor the security staff . . . 
provide any information for the medical chart. As a result of this system, the use and 
reasons for the use of anti-psychotic medication are not always clearly documented in the 
medical chart. A youth may be prescribed a psychotropic medication by a psychiatrist for 
a mental illness or for a contraindicated use, but because the medication would not be 
documented in the medical chart, the facility physician could be unaware of the exis-
2010] "THEY USE IT LIKE CANDY" 511 
scribed drugs or the side effects on children’s health is often inadequate 
or absent.282 Additionally, at least one government investigation unco-
vered serious breaches in security in the monitoring of distribution of 
drugs, resulting in numerous instances of hoarding and illicit trafficking 
of medication among youth.283 The DOJ’s assessment of conditions at a 
Georgia juvenile prison succinctly captures the essence of the egregious 
departures from sound medical practice across the nation: 
For example, at the Bill E. Ireland YDC, there were no diagnoses or in-
itial psychiatric evaluations prior to beginning medications; no interac-
tion between psychiatrists and medical or direct care staff; insufficient 
monitoring of the efficacy and side effects of drugs; inadequate follow-
up and re-evaluation; and deficient record keeping. The facility’s con-
tract psychiatrist has prescribed dangerously high dosages of medica-
                                                                                                                                     
tence, purpose, or reason for the medication. This leads to a dangerous situation where 
follow-up on medical care may not be done, or adverse drug interactions may occur.”); 
New York Findings Letter, supra note 277, at 20 (“Across the four facilities, there was a 
pervasive lack of documentation of either the target symptoms for the medications or 
monitoring of the effectiveness (or lack thereof) of medication on those target symp-
toms.”). 
 282. Price, supra note 2 (“Wards [in California Youth Authority facilities] were pre-
scribed Cylert, an [internationally controlled] central-nervous-system stimulant that can 
cause liver damage, but no follow-up liver-function tests were ordered.”). Concluding 
that “the overall risk of liver toxicity from Cylert and generic pemoline products out-
weighs the benefits of this drug,” the FDA withdrew approval of Cylert in 2005. See 
Safety Information, Food & Drug Admin., MedWatch, Cylert and Generic Pemoline 
Products, http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanProducts 
/ucm151073.htm; see also New York Findings Letter, supra note 277, at 21 (finding “sub-
stantial departures from generally accepted professional standards” in facilities’ psycho-
tropic medication practices; no charts were found “where youth were being monitored for 
abnormal involuntary movement. . . . [T]he psychiatrists confirmed that they did not rou-
tinely monitor for involuntary movements but one agreed that ‘it would probably be a 
good idea.’ In addition, there are no system-wide protocols specifying which medications 
require which laboratory examinations. Where laboratory examinations were conducted, 
they omitted critical information.”). 
 283. See, e.g., Letter from R. Alexander Acosta, Assistant Att’y Gen., U.S. Dep’t of 
Justice, to Brad Henry, Governor, State of Oklahoma 13 (June 8, 2005), available at 
http://www.justice.gov/crt/split/documents/split_rader_findlet_6-15-05.pdf. The investi-
gators found that children “regularly hoard medication and either share it with or sell it to 
other youth.” Id. In one instance, “a youth provided two pills of a psychotropic medica-
tion and two pills of an anti-depressant to two other youth who crushed the pills and 
snorted them. In another example, “a male youth swallowed eight pills during medication 
distribution. Over a two-week-period the youth had ‘cheeked’ some of his own medica-
tion and had received prescription medication from other youth.” Id. In yet another situa-
tion “a male youth provided 13 pills to three other youth. The three youth took the pills 
without knowing what they were. One youth, with slurred speech, informed staff that he 
wanted to fly like Superman.” Id. 
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tions (sometimes beginning youths on dosages five or six times accept-
able starting dosages) without adequate evaluation or monitoring for se-
rious side effects, as well as continued youths on non-therapeutic do-
sages of medications without taking adequate steps to determine their 
efficacy.284 
The foregoing examples, documented by the United States govern-
ment, clearly establish a nationwide pattern and practice of serious de-
partures from sound medical practice in the use of psychotropic drugs 
among state-involved children in juvenile facilities. Similar conditions 
exist among children in foster care.285 To comply with the sound medical 
practice requirement in Article 9 of the 1971 Convention, the United 
States government must promulgate nationally applicable standards and 
guidelines to protect state-involved children from these rampant and im-
proper breaches of proper medical protocol. 
CONCLUSION 
The conditions under which children in the foster care and juvenile jus-
tice systems are prescribed psychotropic medications in the United States 
do not come close to satisfying the standards established by the 1971 
United Nations Convention on Psychotropic Substances. In the final 
analysis, the indiscriminate and unchecked use of psychotropic medica-
tions is a threat of great magnitude to the health, safety, and well-being 




I’m a child in a cage, 
locked in a mental hospital for being underage 
and not being on DCF’s “page”, 
I’m the property of the state 
And of workers earning minimum wage, 
I’m restrained and tranquilized 
Like an animal on a stage, 
I’m shut-up and shut-away 
But I’m not allowed to feel rage, 
I’m just a child in foster care 
Growing up in a cage. 
-Anna, Age 16286 
                                                                                                                                     
 284. Georgia Findings Letter, supra note 208. 
 285. See generally GABRIEL MYERS WORK GROUP, supra note 19; STRAYHORN, supra 
note 101. 
 286. Florida’s Children First, Reflections of Former Foster Children, http://floridas 
childrenfirst.org/fcf_RefDocuments_054_mental_health.htm (last visited March 21, 2010). 
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Anna’s words are echoed by Dr. Peter Breggin, who says that 
“[c]hildren don’t have disorders. They live in a disordered world.”287 It is 
hoped that this Article will precipitate action by the United States gov-
ernment to closely study its obligations under the 1971 Convention on 
Psychotropic Substances, and take all necessary and appropriate meas-
ures to comply with its mandates. The government must act swiftly and 
aggressively to alleviate the unnecessary suffering of the thousands of 
children across America for whom the experience of being “restrained 
and tranquilized” has become disturbingly commonplace. 
                                                                                                                                     
 287. BREGGIN & BREGGIN, supra note 191, at 86. 
